

=> fil reg

FILE 'REGISTRY' ENTERED AT 14:14:58 ON 09 MAR 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 7 MAR 2003 HIGHEST RN 497212-14-3
 DICTIONARY FILE UPDATES: 7 MAR 2003 HIGHEST RN 497212-14-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
 PROPERTIES for more information. See STNote 27, Searching Properties
 in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>


=> d ide can 120

L20 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
 RN 426832-86-2 REGISTRY
 CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, mixt. with 8-chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C35 H36 Cl N O3 S . C19 H19 Cl N2
 CI MXS
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 158966-92-8
 CMF C35 H36 Cl N O3 S


Absolute stereochemistry.
 Double bond geometry as shown.



CM 2

Jan Delaval
 Reference Librarian
 Biotechnology & Chemical Library
 Call 1-800-703-308-4498
Jan.Delaval@uspto.gov

CRN 100643-71-8
CMF C19 H19 Cl N2



1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:380104

=> d ide can tot l11

L11 ANSWER 1 OF 8 REGISTRY COPYRIGHT 2003 ACS

RN 150756-35-7 REGISTRY

CN Acetic acid, [2-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]ethoxy]-
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-[2-[4-[Bis(4-fluorophenyl)methyl]piperazin-1-yl]ethoxy]acetic acid

CN **Efletirizine**

CN [2-[4-[Bis(p-fluorophenyl)methyl]-1-piperazinyl]ethoxy]acetic acid

FS 3D CONCORD


MF C21 H24 F2 N2 O3

CI COM

SR World Health Organization

LC STN Files: ADISINSIGHT, ANABSTR, BIOBUSINESS, BIOSIS, CA, CAPLUS, DDFU,
DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, PHAR, PROMT, SYNTHLINE,
TOXCENTER, USAN, USPAT2, USPATFULL

Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

21 REFERENCES IN FILE CA (1962 TO DATE)
21 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 138:153552

REFERENCE 2: 138:73178
 REFERENCE 3: 138:49929
 REFERENCE 4: 137:247716
 REFERENCE 5: 137:15819
 REFERENCE 6: 136:380104
 REFERENCE 7: 136:340592
 REFERENCE 8: 135:111992
 REFERENCE 9: 133:168392
 REFERENCE 10: 132:284236

L11 ANSWER 2 OF 8 REGISTRY COPYRIGHT 2003 ACS

RN 100643-71-8 REGISTRY

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 8-Chloro-11-(4-piperidylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine

CN Aeries

CN Clarinex

CN Descarboethoxyloratadine

CN Desloratadine

CN Neoclarytin


CN Sch 34117

MF C19 H19 Cl N2

CI COM

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CIN, CSCHEM, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PHAR, PROMT, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

156 REFERENCES IN FILE CA (1962 TO DATE)

2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

159 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 138:158851
REFERENCE 2: 138:126978
REFERENCE 3: 138:100180
REFERENCE 4: 138:78570
REFERENCE 5: 138:78456
REFERENCE 6: 138:73178
REFERENCE 7: 138:49929
REFERENCE 8: 138:49404
REFERENCE 9: 138:32765
REFERENCE 10: 138:316

L11 ANSWER 3 OF 8 REGISTRY COPYRIGHT 2003 ACS

RN 90729-43-4 REGISTRY

CN 1-Butanone, 1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Ebastin

CN **Ebastine**


FS 3D CONCORD

MF C32 H39 N O2

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPATFULL
(*File contains numerically searchable property data)

Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

157 REFERENCES IN FILE CA (1962 TO DATE)

8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

158 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 138:147617
REFERENCE 2: 138:130864
REFERENCE 3: 138:73178
REFERENCE 4: 138:66570
REFERENCE 5: 138:49929

REFERENCE 6: 138:250
REFERENCE 7: 137:346182
REFERENCE 8: 137:304292
REFERENCE 9: 137:299872
REFERENCE 10: 137:289046

L11 ANSWER 4 OF 8 REGISTRY COPYRIGHT 2003 ACS

RN 83881-51-0 REGISTRY

CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN **Cetirizine**

FS 3D CONCORD


DR 130018-86-9

MF C21 H25 Cl N2 O3

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS,
BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS,
CIN, CSCHEM, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES,
EMBASE, IPA, MEDLINE, MRCK*, NIOSHTIC, PHAR, PROMT, RTECS*, SYNTHLINE,
TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)

Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

446 REFERENCES IN FILE CA (1962 TO DATE)

9 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

446 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 138:130864
REFERENCE 2: 138:73178
REFERENCE 3: 138:61370
REFERENCE 4: 138:49929
REFERENCE 5: 138:11117
REFERENCE 6: 138:225
REFERENCE 7: 137:389216
REFERENCE 8: 137:362836
REFERENCE 9: 137:362115
REFERENCE 10: 137:345929

L11 ANSWER 5 OF 8 REGISTRY COPYRIGHT 2003 ACS

RN 83799-24-0 REGISTRY

CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-.alpha.,.alpha.-dimethyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-[4-[4-(Hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-.alpha.,.alpha.-dimethylphenylacetic acid

CN Carboxyterfenadine

CN **Fexofenadine**

CN MDL 16455

CN Terfenadine acid metabolite

CN Terfenadine carboxylate


FS 3D CONCORD

DR 159389-12-5, 76815-58-2

MF C32 H39 N O4

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOBUSINESS, BIOSIS, CA, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CIN, CSCHEM, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

215 REFERENCES IN FILE CA (1962 TO DATE)

5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

217 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 138:158763

REFERENCE 2: 138:147480

REFERENCE 3: 138:147184

REFERENCE 4: 138:133411

REFERENCE 5: 138:130864

REFERENCE 6: 138:126952

REFERENCE 7: 138:122559

REFERENCE 8: 138:100652

REFERENCE 9: 138:73178

REFERENCE 10: 138:73082


L11 ANSWER 6 OF 8 REGISTRY COPYRIGHT 2003 ACS

RN 80012-43-7 REGISTRY

CN 1H-Dibenz[c,f]imidazo[1,5-a]azepin-3-amine, 9,13b-dihydro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN (.-.-)-Epinastine
 CN **Epinastine**
 CN WAL 801
 FS 3D CONCORD
 DR 134507-59-8
 MF C16 H15 N3
 CI COM
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,
 CIN, DDFU, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE,
 MRCK*, PHAR, PROMT, SYNTHLINE, TOXCENTER, USAN, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: WHO



****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

125 REFERENCES IN FILE CA (1962 TO DATE)
 4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 125 REFERENCES IN FILE CAPLUS (1962 TO DATE)


REFERENCE 1: 138:73178
 REFERENCE 2: 138:49929
 REFERENCE 3: 137:362836
 REFERENCE 4: 137:358089
 REFERENCE 5: 137:268446
 REFERENCE 6: 137:247716
 REFERENCE 7: 137:72847
 REFERENCE 8: 137:41740
 REFERENCE 9: 136:380104
 REFERENCE 10: 136:374833

L11 ANSWER 7 OF 8 REGISTRY COPYRIGHT 2003 ACS
 RN 75970-99-9 REGISTRY
 CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-4-piperidinyl- (9CI)
 (CA INDEX NAME)
 OTHER NAMES:
 CN 1-(4-Fluorobenzyl)-2-(4-piperidylamino)benzimidazole
 CN 1-(4-Fluorophenylmethyl)-2-(4-piperidylamino)benzimidazole
 CN **Norastemizole**
 CN Soltara
 CN T 1348
 CN Tecastemizole

MF C19 H21 F N4

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, BEILSTEIN*, BIOBUSINESS,
 BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CEN, CIN, CSCHEM, DDFU, DRUGNL,
 DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, PHAR, PROMT,
 SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

62 REFERENCES IN FILE CA (1962 TO DATE)

62 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 138:127034

REFERENCE 2: 138:73178

REFERENCE 3: 138:49929

REFERENCE 4: 137:375287

REFERENCE 5: 137:247716

REFERENCE 6: 137:241682

REFERENCE 7: 137:109489

REFERENCE 8: 136:380104

REFERENCE 9: 136:355482

REFERENCE 10: 136:340592

L11 ANSWER 8 OF 8 REGISTRY COPYRIGHT 2003 ACS

RN 68844-77-9 REGISTRY

CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Astemisan

CN **Astemizole**

CN Hismanal

CN Histamen

CN Histaminos

CN Histazol

CN Kelp

CN Laridal

CN Metodik

CN Novo-Nastizol A


CN Paralergin

CN R 42512

CN R 43512

CN Retolen

CN Waruzol
 MF C28 H31 F N4 O
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS,
 CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU,
 DRUGUPDATES, EMBASE, HSDB*, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC,
 PHAR, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2,
 USPATFULL, VETU
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

418 REFERENCES IN FILE CA (1962 TO DATE)
 15 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 420 REFERENCES IN FILE CAPLUS (1962 TO DATE)


REFERENCE 1: 138:147617
 REFERENCE 2: 138:131056
 REFERENCE 3: 138:78456
 REFERENCE 4: 138:73178
 REFERENCE 5: 138:66653
 REFERENCE 6: 138:49929
 REFERENCE 7: 138:44736
 REFERENCE 8: 138:33365
 REFERENCE 9: 138:32765
 REFERENCE 10: 137:358177

=> d ide can tot 118

L18 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2003 ACS
 RN 220927-27-5 REGISTRY
 CN Cyclopropaneacetic acid, 1-[[[(1S)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C35 H36 Cl N O3 S
 CI COM

SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 130:213725

L18 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2003 ACS
RN 220927-26-4 REGISTRY
CN Cyclopropaneacetic acid, 1-[[[1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C35 H36 Cl N O3 S
SR CA
LC STN Files: CA, CAPLUS

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 130:213725

L18 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2003 ACS
RN 158966-92-8 REGISTRY
CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-

quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio)methyl]- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Cyclopropaneacetic acid, 1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio)methyl]-, [R-(E)]-

OTHER NAMES:

CN **Montelukast**

FS STEREOSEARCH

MF C35 H36 Cl N O3 S

CI COM

SR World Health Organization


LC STN Files: ADISINSIGHT, ADISNEWS, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CHEMCATS, CIN, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PHARMASEARCH, PROMT, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO

Absolute stereochemistry.

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

153 REFERENCES IN FILE CA (1962 TO DATE)

2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

153 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 138:130852

REFERENCE 2: 138:117473

REFERENCE 3: 138:117398

REFERENCE 4: 138:117386

REFERENCE 5: 138:73178

REFERENCE 6: 138:39187

REFERENCE 7: 138:19255


REFERENCE 8: 137:379839

REFERENCE 9: 137:362833

REFERENCE 10: 137:362325

L18 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2003 ACS
RN 142522-28-9 REGISTRY
CN Cyclopropaneacetic acid, 1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, (R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C35 H36 Cl N O3 S
CI COM
SR CA
LC STN Files: ADISINSIGHT, CA, CAPLUS, DRUGPAT, DRUGUPDATES, SYNTHLINE, USPATFULL

Absolute stereochemistry.
Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1962 TO DATE)
3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 125:142784

REFERENCE 2: 123:313787

REFERENCE 3: 117:90163

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 14:16:14 ON 09 MAR 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Mar 2003 VOL 138 ISS 11
 FILE LAST UPDATED: 7 Mar 2003 (20030307/ED)

This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d all hitstr tot 189

L89 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2003 ACS

AN 2002:392238 HCAPLUS

DN 136:380104

TI Antihistamine, alone or with leukotriene antagonist,
 for the prevention and treatment of cardiovascular disease

IN Harris, Alan G.; Medeiros, Paul T.

PA Schering Corporation, USA

SO U.S. Pat. Appl. Publ., 8 pp.

CODEN: USXXCO

DT Patent

LA English

IC ICM A61K031-496

ICS A61K031-473


NCL 514290000

CC 1-8 (Pharmacology)

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 2002061902	A1	20020523	US 2001-21189	20011030	<--
	WO 2002067938	A2	20020906	WO 2001-US45481	20011026	<--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
PRAI	US 2000-244365P	P	20001030	<--		
AB	Methods are disclosed for treating and/or preventing a cardiovascular disease in a human suffering from an allergic and/or inflammatory condition of the skin or upper airway passages or cardiovascular disease by administering an effective amt. of an antihistamine, preferably desloratadine, alone or in admixt. with an effective amt. of at least one leukotriene antagonist, preferably montelukast.					
ST	antihistamine leukotriene antagonist cardiovascular disease; desloratadine montelukast cardiovascular disease					
IT	Animal cell line (HUVEC; antihistamine, alone or with leukotriene antagonist, for prevention and treatment of cardiovascular disease)					
IT	Nose (allergic rhinitis, seasonal and perennial; antihistamine, alone or with leukotriene antagonist, for prevention and treatment of cardiovascular disease)					
IT	Asthma Dermatitis (allergic; antihistamine, alone or with leukotriene antagonist, for prevention and treatment of cardiovascular disease)					
IT	Respiratory tract (allergy, upper airway; antihistamine, alone or with leukotriene antagonist, for prevention and treatment of					

- cardiovascular disease)
- IT Antihistamines
Cardiovascular agents
Dermatitis
Human
Leukotriene antagonists
Urticaria
(antihistamine, alone or with leukotriene
antagonist, for prevention and treatment of cardiovascular disease)
- IT Dermatitis
(atopic; antihistamine, alone or with leukotriene
antagonist, for prevention and treatment of cardiovascular disease)
- IT Eosinophil
(chemotaxis and adhesion; antihistamine, alone or with
leukotriene antagonist, for prevention and treatment of
cardiovascular disease)
- IT Adhesion, biological
Chemotaxis
(eosinophil; antihistamine, alone or with leukotriene
antagonist, for prevention and treatment of cardiovascular disease)
- IT Respiratory tract
(inflammation, upper airway; antihistamine, alone
or with leukotriene antagonist, for prevention and treatment
of cardiovascular disease)
- IT 68844-77-9, Astemizole 75970-99-9,
Norastemizole 80012-43-7, Epinastine
83799-24-0, Fexofenadine 83881-51-0,
Cetirizine 90729-43-4, Ebastine
100643-71-8, Desloratadine 150756-35-7,
Efletirizine 158966-92-8, Montelukast
426832-86-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(antihistamine, alone or with leukotriene
antagonist, for prevention and treatment of cardiovascular disease)
- IT 68844-77-9, Astemizole 75970-99-9,
Norastemizole 80012-43-7, Epinastine
83799-24-0, Fexofenadine 83881-51-0,
Cetirizine 90729-43-4, Ebastine
100643-71-8, Desloratadine 150756-35-7,
Efletirizine 158966-92-8, Montelukast
426832-86-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(antihistamine, alone or with leukotriene
antagonist, for prevention and treatment of cardiovascular disease)
- RN 68844-77-9 HCAPLUS
- CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-
methoxyphenyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 75970-99-9 HCAPLUS


CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-4-piperidiny]- (9CI)
(CA INDEX NAME)




RN 80012-43-7 HCAPLUS
CN 1H-Dibenz[c,f]imidazo[1,5-a]azepin-3-amine, 9,13b-dihydro- (9CI) (CA INDEX NAME)




RN 83799-24-0 HCAPLUS
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidiny]butyl]-.alpha.,.alpha.-dimethyl- (9CI) (CA INDEX NAME)



RN 83881-51-0 HCAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)




RN 90729-43-4 HCAPLUS
CN 1-Butanone, 1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidiny]- (9CI) (CA INDEX NAME)




RN 100643-71-8 HCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)- (9CI) (CA INDEX NAME)



RN 150756-35-7 HCAPLUS


CN Acetic acid, [2-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 158966-92-8 HCAPLUS

CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 426832-86-2 HCAPLUS


CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, mixt. with 8-chloro-6,11-dihydro-11-(4-piperidinyldiene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (9CI) (CA INDEX NAME)

CM 1

CRN 158966-92-8

CMF C35 H36 Cl N O3 S


Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 100643-71-8

CMF C19 H19 Cl N2



L89 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2003 ACS

AN 2001:780657 HCAPLUS

DN 135:335151

TI Method and **compositions** for the treatment of allergic conditions using PGD2 receptor antagonists

IN Jones, Thomas R.

PA Merck Frosst Canada + Co., Can.

SO PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-00

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1, 25

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001078697	A2	<u>20011025</u>	WO 2001-CA491	<u>20010409</u> <--
	WO 2001078697	A3	20020801		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	US 2001051624	A1	20011213	US 2001-818885	20010327 <--
	EP 1274457	A2	20030115	EP 2001-923433	20010409 <--
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
PRAI	US 2000-196641P	P	20000412 <--		
	WO 2001-CA491	W	20010409		
AB	A method for the treatment of allergic conditions, e.g., allergic rhinitis, comprises administering an effective amt. of a prostaglandin D2 (PGD2) receptor antagonist and an effective amt. of at least one other therapeutically active compd. selected from a histamine H1 antagonist and a leukotriene antagonist. The histamine H1 antagonist is selected from loratadine , descarboethoxyloratadine , cetirizine , levocetirizine and fexofenadine , while the leukotriene D4 antagonist is selected from zafirlukast , montelukast and pranlukast . The allergic condition is allergic rhinitis. For example, the synthesis of 2-[(1R)-9-(4-chlorobenzyl)-8-((R)-methylsulfinyl)-2,3,4,9-tetrahydro-1H-carbazol-1-yl]acetic acid and 2-[(1R)-9-(4-chlorobenzyl)-8-((S)-methylsulfinyl)-2,3,4,9-tetrahydro-1H-carbazol-1-yl]acetic acid (I) was described. The single administration of the histamine H1 antagonist mepyramine (5 mg/kg, i.p.) or compd. I (1 mg/kg, i.p.) 60 min prior to ovalbumin nasal antigen challenge in guinea pigs had no significant effect on the increase in intranasal pressure. However, in similar exptl. conditions, the increase in intranasal pressure produced by ovalbumin was significantly blocked by the combination of mepyramine (5 mg/kg, i.p.) and compd. I (0.3 or 1 mg mg/kg, i.p.).				
ST	prostaglandin receptor leukotriene antagonist				
	antihistamine antiallergy; nasal spray allergic rhinitis				
IT	Prostanoid receptors				
	RL: BSU (Biological study, unclassified); BIOL (Biological study) (DP, antagonists; compns. contg. prostaglandin D2 receptor antagonist, antihistamine and leukotriene antagonist for allergy treatment)				


- IT **Antihistamines**
(H1; **compns.** contg. prostaglandin D2 receptor antagonist, **antihistamine** and **leukotriene** antagonist for allergy treatment)
- IT **Nose**
(allergic rhinitis; **compns.** contg. prostaglandin D2 receptor antagonist, **antihistamine** and **leukotriene** antagonist for allergy treatment)
- IT **Allergy inhibitors**
Leukotriene antagonists
(**compns.** contg. prostaglandin D2 receptor antagonist, **antihistamine** and **leukotriene** antagonist for allergy treatment)
- IT **Drug delivery systems**
(nasal sprays; **compns.** contg. prostaglandin D2 receptor antagonist, **antihistamine** and **leukotriene** antagonist for allergy treatment)
- IT 73836-78-9, **Leukotriene D4**
RL: BSU (Biological study, unclassified); BIOL (Biological study) (antagonists; **compns.** contg. prostaglandin D2 receptor antagonist, **antihistamine** and **leukotriene** antagonist for allergy treatment)
- IT 367958-38-1P 367958-41-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**compns.** contg. prostaglandin D2 receptor antagonist, **antihistamine** and **leukotriene** antagonist for allergy treatment)
- IT 59-33-6, Mepyramine 79794-75-5, **Loratadine** 83799-24-0, **Fexofenadine** 83881-51-0, **Cetirizine** 100643-71-8, **Descarboethoxyloratadine** 103177-37-3, **Pranlukast** 107753-78-6, **Zafirlukast** 130018-77-8, **Levocetirizine** 158966-92-8, **Montelukast**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**compns.** contg. prostaglandin D2 receptor antagonist, **antihistamine** and **leukotriene** antagonist for allergy treatment)
- IT 870-50-8, Di-tert-butyl azodicarboxylate 2987-53-3, 2-(Methylthio)aniline 19614-16-5 24731-17-7, Ethyl 2-cyclohexanoneacetate
RL: RCT (Reactant); RACT (Reactant or reagent)
(**compns.** contg. prostaglandin D2 receptor antagonist, **antihistamine** and **leukotriene** antagonist for allergy treatment)
- IT 60481-33-6P 88965-67-7P 121083-42-9P 367958-15-4P 367958-20-1P 367958-28-9P 367958-31-4P 367958-35-8P 367958-36-9P 369644-71-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(**compns.** contg. prostaglandin D2 receptor antagonist, **antihistamine** and **leukotriene** antagonist for allergy treatment)
- IT 41598-07-6, Prostaglandin D2
RL: BSU (Biological study, unclassified); BIOL (Biological study) (receptors, antagonists; **compns.** contg. prostaglandin D2 receptor antagonist, **antihistamine** and **leukotriene** antagonist for allergy treatment)
- IT 83799-24-0, **Fexofenadine** 83881-51-0, **Cetirizine** 100643-71-8, **Descarboethoxyloratadine** 158966-92-8, **Montelukast**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compns. contg. prostaglandin D2 receptor antagonist, antihistamine and leukotriene antagonist for allergy treatment)


RN 83799-24-0 HCAPLUS

CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-.alpha.,.alpha.-dimethyl- (9CI) (CA INDEX NAME)




RN 83881-51-0 HCAPLUS

CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 100643-71-8 HCAPLUS


CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)- (9CI) (CA INDEX NAME)



RN 158966-92-8 HCAPLUS

CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L89 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2003 ACS

AN 2001:617861 HCAPLUS

DN 135:185482

TI Novel **combination** of non-sedative anti-histamines containing substances which influence the action of **leukotriene**, for treating rhinitis/conjunctivitis

IN Poppe, Hildegard; Engel, Juergen; Szelenyi, Istvan

PA Asta Medica Aktiengesellschaft, Germany

SO PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DT Patent

LA German

IC ICM A61K045-00

CC 63-6 (Pharmaceuticals)

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001060407	A2	20010823	WO 2001-EP1190	20010205 <--
	WO 2001060407	A3	20020307		
	W:	AU, BG, BR, BY, CN, CZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, UZ, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR			
	DE 10007203	A1	20010823	DE 2000-10007203	20000217 <--
	EP 1265615	A2	20021218	EP 2001-911591	20010205 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	US 2001025040	A1	20010927	US 2001-784640	20010215 <--
	US 6436924	B2	20020820		
	NO 2002003818	A	20020812	NO 2002-3818	20020812 <--
PRAI	DE 2000-10007203	A	20000217 <--		
	WO 2001-EP1190	W	20010205		
AB	The invention relates to a pharmaceutical combination to be administered topically or orally of a non-sedative anti-histamine, with the exception of compds. of the loratadine type, and a leukotriene antagonist, selected from a leukotriene D4 antagonist, or a 5-lipoxygenase inhibitor, or a FLAP antagonist and optionally conventional, physiol. harmless supports, extenders and auxiliary agents, for the prophylaxis and treatment of allergic and/or vasomotor rhinitis or allergic conjunctivitis. Thus a nasal spray contained in 100 mL aq. soln. (g): montelukast 1.0000 azelastine hydrochloride 0.1000; Avicel RC591 1.1000; Polysorbat 80 0.1000; sorbitol soln. (70%) 6.0000; sodium EDTA 0.0500; benzalkonium chloride 0.0200.				
ST	antihistamine leukotriene antagonist combination eye nose drop rhinitis conjunctivitis				

- IT Proteins, specific or class
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (FLAP (arachidonate lipoxygenase-activating protein), antagonist;
 combination of non-sedative anti-histamines contg.
 substances which influence action of leukotriene, for
 treating rhinitis/conjunctivitis)
- IT Eye, disease
 (allergic conjunctivitis; combination of non-sedative anti-histamines contg. substances which influence action of leukotriene, for treating rhinitis/conjunctivitis)
- IT Antihistamines
 Leukotriene antagonists
 (combination of non-sedative anti-histamines contg. substances which influence action of leukotriene, for treating rhinitis/conjunctivitis)
- IT Drug delivery systems
 (nasal; combination of non-sedative anti-histamines contg. substances which influence action of leukotriene, for treating rhinitis/conjunctivitis)
- IT Drug delivery systems
 (ophthalmic; combination of non-sedative anti-histamines contg. substances which influence action of leukotriene, for treating rhinitis/conjunctivitis)
- IT Drug delivery systems
 (oral; combination of non-sedative anti-histamines contg. substances which influence action of leukotriene, for treating rhinitis/conjunctivitis)
- IT Nose
 (rhinitis; combination of non-sedative anti-histamines contg. substances which influence action of leukotriene, for treating rhinitis/conjunctivitis)
- IT Drug delivery systems
 (topical; combination of non-sedative anti-histamines contg. substances which influence action of leukotriene, for treating rhinitis/conjunctivitis)
- IT 73836-78-9, Leukotriene D4
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (antagonist; combination of non-sedative anti-histamines contg. substances which influence action of leukotriene, for treating rhinitis/conjunctivitis)
- IT 79307-93-0, Azelastine hydrochloride 158966-92-8, Montelukast 197584-39-7, AWD 23-115
 RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (combination of non-sedative anti-histamines contg. substances which influence action of leukotriene, for treating rhinitis/conjunctivitis)
- IT 68844-77-9, Astemizole 79516-68-0, Levocabastine 79672-88-1, Piriprost 83799-24-0, Fexofenadine 83881-51-0, Cetirizine 103177-37-3, Pranlukast 107753-78-6, Zafirlukast 108612-45-9, Mizolastine 111406-87-2, Zileuton 118414-82-7, MK-886 128253-31-6, Bay x 1005 147030-01-1, MK-591
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination of non-sedative anti-histamines contg. substances which influence action of leukotriene, for treating rhinitis/conjunctivitis)
- IT 79794-75-5, Loratadine
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (combination of non-sedative anti-histamines with the exception of loratadine-type compds. contg. substances


which influence action of **leukotriene**, for treating rhinitis/conjunctivitis)

- IT 80619-02-9, 5-Lipoxygenase
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (inhibitor; **combination** of non-sedative anti-histamines contg. substances which influence action of **leukotriene**, for treating rhinitis/conjunctivitis)
- IT 158966-92-8, Montelukast
 RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (**combination** of non-sedative anti-histamines contg. substances which influence action of **leukotriene**, for treating rhinitis/conjunctivitis)
- RN 158966-92-8 HCAPLUS
- CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



- IT 68844-77-9, Astemizole 83799-24-0, Fexofenadine 83881-51-0, Cetirizine
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**combination** of non-sedative anti-histamines contg. substances which influence action of **leukotriene**, for treating rhinitis/conjunctivitis)
- RN 68844-77-9 HCAPLUS
- CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




- RN 83799-24-0 HCAPLUS
- CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-.alpha.,.alpha.-dimethyl- (9CI) (CA INDEX NAME)



RN 83881-51-0 HCAPLUS

CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-(9CI) (CA INDEX NAME)



L89 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2003 ACS

AN 2001:79915 HCAPLUS

DN 135:131511

TI Present and potential therapy for allergic rhinitis. A review

AU Reichmuth, Daniel; Lockey, Richard F.

CS Division of Allergy and Immunology, University of South Florida College of Medicine, Tampa, FL, USA

SO BioDrugs (2000), 14(6), 371-387

CODEN: BIDRF4; ISSN: 1173-8804

PB Adis International Ltd.

DT Journal; General Review

LA English

CC 1-0 (Pharmacology)

Section cross-reference(s): 2, 15

AB A review with 160 refs. Allergic rhinitis can affect up to one-fifth of the population and the economic impact is increasing. H1 receptor antagonists were the first major pharmacol. treatment, but the assocd. sedation limited their use. The 2 initial second generation less sedating **antihistamines**, **astemizole** and **terfenadine**, were found to prolong the cardiac QTc interval, esp. when administered with other medications metabolized by the same cytochrome (CYP) P 450 isoenzyme, CYP3A4. Other second generation **antihistamines**, **fexofenadine**, **loratadine** and **cetirizine**, do not cause clin. significant cardiac QTc interval prolongation. Two newer agents, **ebastine** and **mizolastine**, are also effective in the treatment of allergic rhinitis. **Ebastine**, however, prolongs the cardiac QTc interval in lab. animals and humans, the clin. significance of which is unknown. **Desloratadine** and **norastemizole**, metabolites of **loratadine** and **astemizole**, resp., are 2 other second generation **antihistamines** found to be effective treatments for seasonal allergic rhinitis. Unlike their parent compds., they do not prolong the cardiac QTc interval. All clin. available intranasal corticosteroids are effective in the treatment of allergic rhinitis, but studies to evaluate possible long term systemic adverse effects are limited. Mometasone furoate and fluticasone propionate have lower oral bioavailability compared with other corticosteroids that are given intranasally. This may be important, since it is likely that some of the intranasal corticosteroid is ingested. Two 1-yr growth studies in children indicated that intranasal beclomethasone dipropionate given twice daily reduces growth velocity, whereas intranasal mometasone furoate given once daily in the morning does not. Other studies are needed. Most but not all studies have shown that **leukotriene** antagonists are

effective in the treatment of allergic rhinitis. H1 receptor antagonists are not very effective in reducing nasal congestion, but **leukotriene** antagonists do attenuate this symptom. Furthermore, one study demonstrates an additive benefit in treating allergic rhinitis with the **combination** of a H1 receptor and **leukotriene** antagonist. Clin. trials have demonstrated that anti-Ig (Ig) E is effective in the treatment of seasonal allergic rhinitis when free IgE is reduced to <25 .mu.g/L. The redn. of total IgE is dose dependent and s.c. and i.v. administration are both effective. Immunotherapy is also an effective treatment for allergic rhinitis. CpG oligonucleotides is a novel adjuvant for allergen immunotherapy. This adjuvant used in a murine model shifts the immune response away from the allergic or TH2 phenotype. Studies in humans have not been performed.

ST review **antihistamine leukotriene** antagonist
immunotherapy allergic rhinitis

IT **Antihistamines**

(H1; present and potential therapy for allergic rhinitis in humans)

IT **Antihistamines**

Hay fever

Immunotherapy

Leukotriene antagonists

(present and potential therapy for allergic rhinitis in humans)

IT Corticosteroids, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(present and potential therapy for allergic rhinitis in humans)

IT 50679-08-8, Terfenadine 68844-77-9, **Astemizole**
90729-43-4, **Ebastine**

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(present and potential therapy for allergic rhinitis in humans)

IT 75970-99-9, **Norastemizole** 79794-75-5,
Loratadine 80474-14-2, **Fluticasone propionate** 83799-24-0
, **Fexofenadine** 83881-51-0, **Cetirizine**
83919-23-7, **Mometasone furoate** 100643-71-8,
Desloratadine 108612-45-9, **Mizolastine**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(present and potential therapy for allergic rhinitis in humans)

IT 5534-09-8, **Beclomethasone dipropionate**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(present and potential therapy for allergic rhinitis in humans)

RE.CNT 160 THERE ARE 160 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Adelroth, E; J Allergy Clin Immunol 2000, V106(2), P253 HCAPLUS
- (2) Affrime, M; J Allergy Clin Immunol 2000, V105(1 Pt 2), PS386
- (3) Agertoft, L; J Allergy Clin Immunol 1999, V104, P948 HCAPLUS
- (4) Allen, D; J Allergy Clin Immunol 1994, V93(6), P967 MEDLINE
- (5) Allen, D; J Allergy Clin Immunol 2000, V106(4), PS179-90 HCAPLUS
- (6) American Academy of Allergy, Asthma, and Immunology (AAAAI), Task Force on Allergic Disorders; Executive summary report 1998
- (7) Amiri, P; J Exp Med 1994, V180, P43 HCAPLUS
- (8) Andersson, M; J Allergy Clin Immunol 1988, V82, P1019 MEDLINE
- (9) Anon; Allergy 1998, V53(44 Suppl), P1
- (10) Anthes, J; J Allergy Clin Immunol 2000, V105(1 Pt 2), PS385
- (11) Arbesman, C; N Y State J Med 1947, V47, P1775
- (12) Aventis Pharmaceuticals; Fexofenadine hydrochloride prescribing information, package insert 2000
- (13) Aventis Pharmaceuticals Inc; Allergy Today 2000

- (14) Bachert, C; Allergy 1998, V53, P969 HCAPLUS
- (15) Banfield, C; J Allergy Clin Immunol 2000, V105(1 Pt 2), PS383
- (16) Bascom, R; J Allergy Clin Immunol 1988, V81, P580 MEDLINE
- (17) Bende, M; Allergy 1987, V42, P512 MEDLINE
- (18) Berger, W; Ann Allergy Immunol 1999, V82(6), P535 HCAPLUS
- (19) Berkowitz, R; Allergy Asthma Proc 1999, V20, P167 HCAPLUS
- (20) Bohle, B; Eur J Immunol 1999, V29, P2344 HCAPLUS
- (21) Bousquet, J; Allergy 1999, V54, P562 HCAPLUS
- (22) Busse, W; Clin Exp Allergy 1996, V26, P868 HCAPLUS
- (23) Campbell, A; Drugs 1996, V52(Suppl 1), P15
- (24) Canonica, W; Clin Exp Allergy 1999, V29(Suppl 3), P69
- (25) Casale, T; Allergy Asthma Proc 1999, V20, P193 HCAPLUS
- (26) Casale, T; J Allergy Clin Immunol 1997, V100(1), P110 MEDLINE
- (27) Casale, T; J Allergy Clin Immunol 2000, V104(1 Pt 2), PS357
- (28) Church, M; Clin Exp Allergy 1999, V29(Suppl 3), P39
- (29) Ciprandi, G; Clin Exp Allergy 1997, V27, P1175 HCAPLUS
- (30) Ciprandi, G; Clin Exp Allergy 1999, V29(Suppl 3), P49
- (31) Ciprandi, G; J Allergy Clin Immunol 1996, V98, P1088 HCAPLUS
- (32) Cohen, J; Science 1995, V270(10), P908
- (33) Cohen, S; Allergens and allergen immunotherapy. 2nd ed 1999, P1 HCAPLUS
- (34) Cookson, W; Nature 1999, V402, PB5-11 HCAPLUS
- (35) Corne, J; J Clin Invest 1997, V99(5), P879 HCAPLUS
- (36) Corren, J; J Allergy Clin Immunol 1999, V104, PS144-9 HCAPLUS
- (37) Cuss, F; Clin Exp Allergy 1999, V29(Suppl 3), P54
- (38) Day, J; J Allergy Clin Immunol 1996, V97, P1050 HCAPLUS
- (39) Day, J; J Allergy Clin Immunol 2000, V105(3), P489 HCAPLUS
- (40) Day, J; J Allergy Clin Immunol 2000, V105(1 Pt 2), PS202
- (41) De Vos, C; Clin Exp Allergy 1999, V29(Suppl 3), P60
- (42) Dechant, K; Drugs 1991, V41(2), P202 HCAPLUS
- (43) Delauche-Cavallier, M; Clin Exp Allergy 1999, V29(Suppl 3), P206
- (44) Derendorf, H; J Clin Pharmacol 1995, V35, P302 MEDLINE
- (45) Des Roches, A; J Allergy Clin Immunol 1997, V99(4), P450 MEDLINE
- (46) Devalia, J; Clin Exp Allergy 1999, V29(Suppl 3), P64
- (47) Donnelly, A; Am J Respir Crit Care Med 1995, V151(6), P1734 MEDLINE
- (48) Emanuel, M; Clin Exp Allergy 1999, V29(Suppl 3), P1
- (49) Estelle, F; J Allergy Clin Immunol 1999, V104, P534
- (50) Flowers, B; Otolaryngol Head Neck Surg 1990, V102, P219 MEDLINE
- (51) Freeman, J; Lancet 1914, VI, P1178
- (52) Frew, A; J Allergy Clin Immunol 1999, V104(2), P267
- (53) Gaglani, B; Ann Allergy Asthma Immunol 1997, V79, P259 MEDLINE
- (54) Gehanno, P; Ann Allergy Asthma Immunol 1996, V76, P507 HCAPLUS
- (55) Ghaffar, O; Am J Respir Cell Mol Biol 1997, V17, P17 HCAPLUS
- (56) Glue, P; J Allergy Clin Immunol 2000, V105(1 Pt 2), PS387
- (57) Grossman, J; J Allergy Clin Immunol 1998, V99(1 Pt 2), PS443
- (58) Gupta, S; J Allergy Clin Immunol 2000, V105(1 Pt 2), PS386-7
- (59) Hamamoto, J; J Appl Physiol 1997, V82(3), P738 HCAPLUS
- (60) Hark, W; The Federal Air Surgeon's Medical Bulletin,
<http://www.faa.gov/avr/aam/fasb597/26.htm> 2000
- (61) Heithoff, K; J Allergy Clin Immunol 2000, V105(1 Pt 2), PS383-4
- (62) Hey, J; Ann Allergy Asthma Immunol 1996, V76(5), P476 HCAPLUS
- (63) Hey, J; J Allergy Clin Immunol 2000, V105(1 Pt 2), PS383
- (64) Hindmarch, I; Clin Exp Allergy 1999, V29(Suppl 3), P133
- (65) Host, A; Allergy 1998, V53, P211
- (66) Howarth, P; Am J Respir Crit Care Med 2000, V161(2 Pt 2), PS133-6 MEDLINE
- (67) Howarth, P; J Allergy Clin Immunol 1999, V104(5), P927 HCAPLUS
- (68) Janiszewski, J; Am J Physiol 1994, V267, PC138-45 HCAPLUS
- (69) Jen, A; J Allergy Clin Immunol 2000, V105(4), P732 HCAPLUS
- (70) Johnstone, D; Pediatr Allergy Immunol 1987, V1(1), P15
- (71) Kips, J; Am J Respir Crit Care Med 1996, V153, P353
- (72) Kita, H; J Allergy Clin Immunol 2000, V106(3), P521 HCAPLUS
- (73) Kline, J; J Immunol 1998, V160, P2555 HCAPLUS
- (74) Knapp, H; N Engl J Med 1990, V323(25), P1745 MEDLINE
- (75) Kohama, Y; J Allergy Clin Immunol 1999, V104(6), P1231 HCAPLUS

- (76) LaForce, C; Ann Allergy Asthma Immunol 1996, V76, P181 HCAPLUS
(77) La Rosa, M; J Allergy Clin Immunol 1999, V104(2 Pt 1), P425 MEDLINE
(78) Ledford, D; Allergens and allergen immunotherapy. 2nd ed 1999, P359
HCAPLUS
(79) Ledford, D; Immunol Allergy Clin N Am 1999, V19(4), P819
(80) Lee, Y; Scand J Immunol 1999, V49, P229 HCAPLUS
(81) Leonard, J; Blood 1997, V90(7), P2541 HCAPLUS
(82) Leynadier, F; Ann Allergy Asthma Immunol 1996, V76, P163 HCAPLUS
(83) Lipworth, B; Arch Intern Med 1999, V159, P941 MEDLINE
(84) Lipworth, B; Thorax 1997, V52, P476 MEDLINE
(85) Litwin, A; J Allergy Clin Immunol 1997, V100, P30 MEDLINE
(86) Livostin Study Group; Allergy 1993, V48, P530
(87) Lockey, R; Ann Allergy Asthma Immunol 1996, V76, P448 HCAPLUS
(88) Lockey, R; J Allergy Clin Immunol 1987, V79, P660 MEDLINE
(89) Loveless, M; Am J Med Sci 1947, V214, P559
(90) Lumry, W; J Allergy Clin Immunol 1999, V104, P150
(91) MICROMEDEX; Healthcare Series, <http://www.micromedex.com> 2000, V104
(92) Malone, D; J Allergy Clin Immunol 1997, V99(1), P22
(93) Markham, A; Drugs 1998, V55(2), P269 HCAPLUS
(94) Martinez, F; J Allergy Clin Immunol 1999, V103(3 Pt 1), P355 MEDLINE
(95) McNeely, W; Drugs 1998, V56(1), P91 HCAPLUS
(96) McTavish, D; Drugs 1989, V38(5), P778 HCAPLUS
(97) Medical Economics Company; Physicians desk reference. 53rd ed 1999, P1095
(98) Medical Economics Company; Physicians desk reference. 53rd ed 1999, P1122
(99) Medical Economics Company; Physicians desk reference. 53rd ed 1999, P1289
(100) Medical Economics Company; Physicians desk reference. 53rd ed 1999, P2448
(101) Medical Economics Company; Physicians desk reference. 53rd ed 1999, P2825
(102) Medical Economics Company; Physicians desk reference. 53rd ed 1999, P3191
(103) Medical Economics Company; Physicians desk reference. 53rd ed 1999, P591
(104) Medical Economics Company; Physicians desk reference. 53rd edition 1999,
P955
(105) Meltzer, E; Ann Allergy 1994, V72, P354 MEDLINE
(106) Meltzer, E; J Allergy Clin Immunol 1988, V82, P447 MEDLINE
(107) Meltzer, E; J Allergy Clin Immunol 2000, V105(5), P917 HCAPLUS
(108) Milgrom, H; N Engl J Med 1999, V341, P1966 HCAPLUS
(109) Moss, A; Clin Exp Allergy 1999, V29(Suppl 3), P200
(110) Mygind, N; Allergy 2000, V55, P421 HCAPLUS
(111) Nayak, A; J Allergy Clin Immunol 2000, V105(1 Pt 2), PS384
(112) Nelson, H; J Allergy Clin Immunol 1999, V104, PS138-43 HCAPLUS
(113) Noon, L; Lancet 1911, VI, P1572
(114) Norman, P; Am J Respir Crit Care Med 1996, V154, P1623 MEDLINE
(115) Onrust, S; Drugs 1998, V56(4), P725 HCAPLUS
(116) Padhi, D; J Allergy Clin Immunol 2000, V105(1 Pt 2), PS385
(117) Passalacqua, G; J Allergy Clin Immunol 1999, V104(5), P964 MEDLINE
(118) Patalano, F; Allergy 1999, V54, P103 HCAPLUS
(119) Pene, J; J Allergy Clin Immunol 1998, V102(4 Pt 1), P571 MEDLINE
(120) Pipkorn, U; N Engl J Med 1987, V316, P1506 MEDLINE
(121) Purello-D'Ambrosio, F; Allergy 1999, V54, P968 MEDLINE
(122) Rachelefsky, G; J Allergy Clin Immunol 1998, V101(Suppl), PS236
(123) Racine-Poon, A; Clin Pharmacol Ther 1997, V62, P675 HCAPLUS
(124) Ratner, P; J Allergy Clin Immunol 1994, V94(5), P818 HCAPLUS
(125) Renwick, A; Clin Exp Allergy 1999, V29(Suppl 3), P116
(126) Renz, H; Inflamm Res 1999, V48(8), P425 HCAPLUS
(127) Ryan, J; J Allergy Clin Immunol 1997, V99(1), P1 HCAPLUS
(128) Sabbah, A; Ann Allergy Asthma Immunol 1999, V83, P319 HCAPLUS
(129) Salmun, L; J Allergy Clin Immunol 2000, V105(1 Pt 2), PS384-5
(130) Schata, M; J Allergy Clin Immunol 1991, V87, P873 MEDLINE
(131) Schenkel, E; Pediatrics, <http://www.pediatrics.org/cgi/content/full/105/e22> 2000, V105(2), PE22 MEDLINE
(132) Schmidt, B; J Clin Pharmacol 1999, V39, P1062 HCAPLUS
(133) Sheffer, A; J Allergy Clin Immunol 1990, V86(6), P1040
(134) Shelton, D; Clin Otolaryngol Allied Sciences 1994, V19(1), P45 MEDLINE
(135) Sibbald, B; Thorax 1991, V46, P895 MEDLINE

- (136) Silverstein, M; J Allergy Clin Immunol 1997, V99(4), P466 HCAPLUS
 (137) Simon, R; Clin Rev Allergy Immunol 1999, V17, P271 HCAPLUS
 (138) Slater, J; Drugs 1999, V57(1), P31 HCAPLUS
 (139) Sohoel, P; J Allergy Clin Immunol 1993, V92, P73 MEDLINE
 (140) Stewart, E; J Allergy Clin Immunol 1992, V90(4 Pt 1), P567
 (141) Storms, W; Allergy Asthma Proc 1997, V18(2), P59 HCAPLUS
 (142) Storms, W; Drugs 1996, V52(Suppl 1), P20
 (143) Storms, W; Ear Nose Throat J 1994, V73(6), P384-6
 (144) Storms, W; J Allergy Clin Immunol 1997, V99(2), PS820-4
 (145) Sur, S; Presented at the American Academy of Allergy Asthma and Immunology Symposium 2000
 (146) The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee; Lancet 1998, V351, P1225
 (147) Theodoropoulos, D; J Allergy Clin Immunol 2000, V105(1), PS72
 (148) Timmerman, H; Clin Exp Allergy 1999, V29(Suppl 3), P13
 (149) Van Deusen, M; Ann Allergy Asthma Immunol 1997, V78, P573 MEDLINE
 (150) Van de Heyning, P; Allergy 1988, V43(5), P386 MEDLINE
 (151) Wang, D; Acta Otolaryngol (Stockh) 1996, V116, P91 MEDLINE
 (152) Weiler, J; Ann Allergy Asthma Immunol 1997, V79, P327 HCAPLUS
 (153) Weiler, J; Ann Intern Med 2000, V132, P354 HCAPLUS
 (154) Weiner, J; BMJ 1998, V317, P1625
 (155) Wihl, J; Allergy 1997, V52, P620 HCAPLUS
 (156) Wilson, A; J Allergy Clin Immunol 1998, V101, P470 HCAPLUS
 (157) Wiseman, L; Drugs 1996, V51(2), P260 HCAPLUS
 (158) Wiseman, L; Drugs 1997, V53(5), P885 HCAPLUS
 (159) Woodwell, D; National Ambulatory Medical Care Survey: 1997 summary. Advance data from vital and health statistics 1999, 305, MEDLINE
 (160) Yap, Y; Clin Exp Allergy 1999, V29(Suppl 3), P174


IT 68844-77-9, Astemizole 90729-43-4,

Ebastine

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (present and potential therapy for allergic rhinitis in humans)


RN 68844-77-9 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 90729-43-4 HCAPLUS


CN 1-Butanone, 1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]- (9CI) (CA INDEX NAME)




IT 75970-99-9, Norastemizole 83799-24-0,
 Fexofenadine 83881-51-0, Cetirizine
 100643-71-8, Desloratadine
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (present and potential therapy for allergic rhinitis in humans)
 RN 75970-99-9 HCAPLUS
 CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-4-piperidinyl- (9CI)
 (CA INDEX NAME)




RN 83799-24-0 HCAPLUS
 CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-
 piperidinyl]butyl]-.alpha.,.alpha.-dimethyl- (9CI) (CA INDEX NAME)



RN 83881-51-0 HCAPLUS
 CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-
 (9CI) (CA INDEX NAME)



RN 100643-71-8 HCAPLUS
 CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-
 piperidinylidene)- (9CI) (CA INDEX NAME)



L89 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2003 ACS
 AN 1999:672612 HCAPLUS
 DN 131:303379
 TI Methods and **compositions** using **norastemizole** in
combination with **leukotriene** inhibitors
 IN Rubin, Paul D.
 PA Sepracor Inc., USA
 SO PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K045-06
 CC 63-6 (Pharmaceuticals)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9952555	A1	19991021	WO 1999-US8078	19990413 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6248308	B1	20010619	US 1998-59572	19980414 <--
	CA 2328075	AA	19991021	CA 1999-2328075	19990413 <--
	AU 9935581	A1	19991101	AU 1999-35581	19990413 <--
	EP 1071462	A1	20010131	EP 1999-917464	19990413 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002511427	T2	20020416	JP 2000-543165	19990413 <--
	US 6372197	B1	20020416	US 2000-721668	20001127 <--
	US 2002086854	A1	20020704	US 2002-84250	20020228 <--
PRAI	US 1998-59572	A	19980414 <--		
	WO 1999-US8078	W	19990413 <--		
	US 2000-721668	A3	20001127		
AB	Methods and pharmaceutical compns. employing norastemizole and a leukotriene inhibitor for the treatment or prevention of <u>inflammation or allergic disorders</u> , such as asthma or the symptoms thereof. Also included are methods and compns. employing norastemizole and a decongestant for the treatment or prevention of inflammation or allergic disorders, such as asthma or the symptoms thereof.				
ST	norastemizole leukotriene inhibitor combination pharmaceutical				
IT	Allergy inhibitors Antiasthmatics Antihistamines Decongestants (pharmaceuticals contg. norastemizole in combination with leukotriene inhibitors)				
IT	Leukotriene antagonists RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceuticals contg. norastemizole in combination with leukotriene inhibitors)				
IT	Drug delivery systems (solids, oral; pharmaceuticals contg. norastemizole in combination with leukotriene inhibitors)				
IT	Drug delivery systems (sprays; pharmaceuticals contg. norastemizole in combination with leukotriene inhibitors)				

IT 80619-02-9, 5-Lipoxygenase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; pharmaceuticals contg. **norastemizole** in
combination with leukotriene inhibitors)

IT 103177-37-3, Pranlukast 107753-78-6, Zafirlukast 158966-92-8,
 Montelukast 171031-57-5 247016-81-5
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (leukotriene antagonist; pharmaceuticals contg.
norastemizole in combination with leukotriene
 inhibitors)

IT 79672-88-1, Piriprost 80809-81-0, Docebenone 111406-87-2, Zileuton
 118414-82-7, MK-886 140841-32-3 147030-01-1, MK-591
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (lipoxygenase inhibitor; pharmaceuticals contg. **norastemizole**
 in **combination with leukotriene** inhibitors)


IT 75970-99-9, Norastemizole
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceuticals contg. **norastemizole in combination**
 with **leukotriene** inhibitors)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE
 (1) Henk, T; US 5714501 A 1998 HCAPLUS
 (2) Procter & Gamble; WO 9746243 A 1997 HCAPLUS
 (3) Schering Corp; WO 9932125 A 1999 HCAPLUS

IT 158966-92-8, Montelukast
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (leukotriene antagonist; pharmaceuticals contg.
norastemizole in combination with leukotriene
 inhibitors)


RN 158966-92-8 HCAPLUS
 CN Cyclopropaneacetic acid, 1-[[[(1R)-1-{3-[(1E)-2-(7-chloro-2-
 quinolinyl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thi
 o]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



IT 75970-99-9, Norastemizole
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceuticals contg. **norastemizole in combination**
 with **leukotriene** inhibitors)

RN 75970-99-9 HCAPLUS
 CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-4-piperidinyl- (9CI)
 (CA INDEX NAME)



L89 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2003 ACS
 AN 1999:672609 HCAPLUS
 DN 131:303378
 TI Methods and compositions using cetirizine in combination with leukotriene inhibitors for treating conditions responsive to leukotriene inhibition
 IN Rubin, Paul D.
 PA Sepracor Inc., USA
 SO PCT Int. Appl., 34 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K045-06
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 28

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9952553	A1	19991021	WO 1999-US8076	19990413 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6384038	B1	20020507	US 1998-59571	19980414 <--
CA 2328073	AA	19991021	CA 1999-2328073	19990413 <--
AU 9935580	A1	19991101	AU 1999-35580	19990413 <--
EP 1071461	A1	20010131	EP 1999-917463	19990413 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002511425	T2	20020416	JP 2000-543163	19990413 <--
US 2002099058	A1	20020725	US 2002-105331	20020326 <--
PRAI US 1998-59571	A	19980414 <--		
WO 1999-US8076	W	19990413 <--		
AB Methods and pharmaceutical compns. employ (+)-, (-)-, or (+-)-cetirizine, or a pharmaceutically acceptable salt thereof, and a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof, or decongestant for the treatment, management, and/or prevention of inflammation, asthma or symptoms thereof, allergic disorders such as allergic rhinitis, and dermatitis. (+)- And (-)-cetirizine-2HCl were prep'd. by hydrolysis of the corresponding (-)- and (+)- acetonitrile derivs.				
ST cetirizine pharmaceutical leukotriene inhibitor				
IT Allergy inhibitors				
Anti-inflammatory agents				
Antiasthmatics				
(prepn. of cetirizine enantiomers for use in combination with leukotriene inhibitors for treating				

conditions responsive to leukotriene inhibition)

IT **Leukotriene antagonists**
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (prepn. of cetirizine enantiomers for use in
 combination with leukotriene inhibitors for treating
 conditions responsive to leukotriene inhibition)

IT 80619-02-9, 5-Lipoxygenase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; prepn. of cetirizine enantiomers for use in
 combination with leukotriene inhibitors for treating
 conditions responsive to leukotriene inhibition)

IT 79672-88-1, Piriprost 80809-81-0, Docebenone 111406-87-2, Zileuton
 118414-82-7, MK-886 140841-32-3, ICI-D2138 147030-01-1, MK-591
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (lipoxygenase inhibitor; prepn. of cetirizine enantiomers for
 use in combination with leukotriene inhibitors for
 treating conditions responsive to leukotriene inhibition)

IT 841-77-0, 1-(Diphenylmethyl)piperazine 36961-64-5, 2-(2-
 Chloroethoxy)acetamide 130018-75-6, Acetonitrile, [2-[4-[(4-
 chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of cetirizine enantiomers for use in
 combination with leukotriene inhibitors for treating
 conditions responsive to leukotriene inhibition)

IT 83881-35-0P 130018-78-9P, Acetonitrile, [2-[4-[(4-
 chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, (-)- 130018-90-5P,
 (+)-1-[4-(4-Chlorophenyl)phenylmethyl]piperazine
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (prepn. of cetirizine enantiomers for use in
 combination with leukotriene inhibitors for treating
 conditions responsive to leukotriene inhibition)

IT 83881-51-0P, Cetirizine 83881-52-1P, Acetic
 acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-,
 dihydrochloride 130018-76-7P, Acetic acid, [2-[4-[(4-
 chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, (S)- 130018-77-8P,
 Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-,
 (R)- 130018-87-0P 163837-48-7P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
 study); PREP (Preparation); USES (Uses)
 (prepn. of cetirizine enantiomers for use in
 combination with leukotriene inhibitors for treating
 conditions responsive to leukotriene inhibition)

IT 103177-37-3, Pranlukast 107753-78-6, Zafirlukast 158966-92-8,
Montelukast 171031-57-5 247016-81-5
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (prepn. of cetirizine enantiomers for use in
 combination with leukotriene inhibitors for treating
 conditions responsive to leukotriene inhibition)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD


RE

(1) Da Motta; BRITISH JOURNAL OF PHARMACOLOGY 1994, V112(1), P111 MEDLINE
 (2) Procter & Gamble; EP 0780127 A 1997 HCAPLUS
 (3) Schering Corp; WO 9932125 A 1999 HCAPLUS

IT 83881-51-0P, Cetirizine 83881-52-1P, Acetic
 acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-,
 dihydrochloride
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
 study); PREP (Preparation); USES (Uses)
 (prepn. of cetirizine enantiomers for use in
 combination with leukotriene inhibitors for treating
 conditions responsive to leukotriene inhibition)


RN 83881-51-0 HCAPLUS

CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-
(9CI) (CA INDEX NAME)



RN 83881-52-1 HCAPLUS

CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-,
dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


IT 158966-92-8, Montelukast

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of **cetirizine** enantiomers for use in
combination with **leukotriene** inhibitors for treating
conditions responsive to **leukotriene** inhibition)

RN 158966-92-8 HCAPLUS

CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L89 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2003 ACS

AN 1999:425758 HCAPLUS

DN 131:63456

TI **Composition** for treating respiratory and skin diseases,
comprising at least one **leukotriene** antagonist and at
least one **antihistamine**

IN Jensen, Peder K.; Lorber, Richard R.; Danzig, Melvyn R.; **Medeiros,**
Paul T.

PA Schering Corporation, USA
 SO PCT Int. Appl., 22 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-55
 ICS A61K031-495; A61K031-47; A61K031-445
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9932125	A1	19990701	WO 1998-US26223	19981221 <--
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	ZA 9811731	A	19990621	ZA 1998-11731	19981221 <--
	CA 2315721	AA	19990701	CA 1998-2315721	19981221 <--
	AU 9919071	A1	19990712	AU 1999-19071	19981221 <--
	BR 9814417	A	20001010	BR 1998-14417	19981221 <--
	EP 1041990	A1	20001011	EP 1998-963828	19981221 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO			
	JP 2001526232	T2	20011218	JP 2000-525116	19981221 <--
	NO 2000003288	A	20000822	NO 2000-3288	20000622 <--
PRAI	US 1997-68638P	P	19971223 <--		
	US 1998-78638P	P	19980319 <--		
	WO 1998-US26223	W	19981221 <--		
AB	The invention relates to a pharmaceutical compn. useful in the treatment of sneezing, itching runny nose, nasal congestion, redness of the eye, tearing, itching of the ears or palate, shortness of breath, inflammation of the bronchial mucosa, reduced Forced Expiratory Vol. In One Second (FEV1), coughs, rash, itchy skin, headaches, and aches and pains assocd. with seasonal allergic rhinitis, perennial allergic rhinitis, common colds, otitis, sinusitis, allergy, asthma, allergic asthma and/or inflammation, in a mammalian organism in need of such treatment. The compn. comprises: (i) an effective amt. of at least one leukotriene antagonist selected from (a) montelukast , (b) 1-(((R)- (3-(2-(6,7- difluoro-2-quinolinyl)ethenyl)phenyl)-3-(2- (2-hydroxy-2-propyl)phenyl)propyl)thio)methylcyclopropaneacetic acid; (c) 1-(((1(R)-3 (3-(2-(2,3-dichlorothieno[3, 2-b]pyridin-5-yl) -(E)-ethenyl)phenyl)-3-(2-(1-hydroxy-1- methylethyl) phenyl)propyl) thio)methyl)cyclopropaneacetic acid; (d) pranlukast; or (f) [2-[[2-(4-tert-butyl-2-thiazolyl) -5-benzofuranyl] oxymethyl]phenyl] acetic acid; or a pharmaceutically acceptable salt thereof; in admixt. with (ii) an effective amt. of at least one antihistamine which is descarboethoxyloratidine, cetirizine, fexofenadine, ebastine, astemizole, norastemizole, epinastine, efletirizine or a pharmaceutically acceptable salt thereof.				
ST	capsule leukotriene antagonist antihistamine ; respiratory skin disease leukotriene antagonist antihistamine				
IT	Drug delivery systems (capsules; compn. for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine)				

IT Analgesics
 Antihistamines
 Antitussives
 Decongestants
 Drug delivery systems
 Expectorants
 Skin, disease
 (compn. for treating respiratory and skin diseases,
 comprising at least one leukotriene antagonist and at
 least one antihistamine)

IT Leukotriene antagonists
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compn. for treating respiratory and skin diseases,
 comprising at least one leukotriene antagonist and at
 least one antihistamine)

IT Respiratory tract
 (disease; compn. for treating respiratory and skin diseases,
 comprising at least one leukotriene antagonist and at
 least one antihistamine)

IT Drug delivery systems
 (gels; compn. for treating respiratory and skin diseases,
 comprising at least one leukotriene antagonist and at
 least one antihistamine)

IT Drug delivery systems
 (powders; compn. for treating respiratory and skin diseases,
 comprising at least one leukotriene antagonist and at
 least one antihistamine)

IT Drug delivery systems
 (tablets; compn. for treating respiratory and skin diseases,
 comprising at least one leukotriene antagonist and at
 least one antihistamine)

IT 90-82-4, Pseudoephedrine 93-14-1, Guaifenesin 125-71-3,
 Dextromethorphan 68844-77-9, Astemizole
 75970-99-9, Norastemizole 80012-43-7,
 Epinastine 83799-24-0, Fexofenadine
 83881-51-0, Cetirizine 90729-43-4,
 Ebastine 100643-71-8 103177-37-3, Pranlukast
 107753-78-6, Zafirlukast 149413-74-1 150756-35-7,
 Eflzetirizine 152952-65-3 158966-92-8,
 Montelukast 172927-32-1
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compn. for treating respiratory and skin diseases,
 comprising at least one leukotriene antagonist and at
 least one antihistamine)


RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE
 (1) Allergan Inc; WO 9303723 A 1993 HCAPLUS
 (2) Boehringer Ingelheim KG; DE 4203201 A 1993
 (3) Dahlen, S; WO 9728797 A 1997 HCAPLUS
 (4) Merck Frosst Canada Inc; EP 0565185 A 1993 HCAPLUS
 (5) Procter & Gamble; EP 0780127 A 1997 HCAPLUS
 (6) Procter & Gamble; WO 9746243 A 1997 HCAPLUS
 (7) Sepracor Inc; WO 9834611 A 1998 HCAPLUS
 (8) Warner Lambert Co; WO 9848839 A 1998 HCAPLUS

IT 68844-77-9, Astemizole 75970-99-9,
 Norastemizole 80012-43-7, Epinastine
 83799-24-0, Fexofenadine 83881-51-0,
 Cetirizine 90729-43-4, Ebastine
 100643-71-8 150756-35-7, Eflzetirizine
 158966-92-8, Montelukast
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compn. for treating respiratory and skin diseases,
 comprising at least one leukotriene antagonist and at

least one antihistamine)


RN 68844-77-9 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 75970-99-9 HCAPLUS

CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 80012-43-7 HCAPLUS

CN 1H-Dibenz[c,f]imidazo[1,5-a]azepin-3-amine, 9,13b-dihydro- (9CI) (CA INDEX NAME)




RN 83799-24-0 HCAPLUS

CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-.alpha.,.alpha.-dimethyl- (9CI) (CA INDEX NAME)




RN 83881-51-0 HCAPLUS

CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)




RN 90729-43-4 HCAPLUS

CN 1-Butanone, 1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 100643-71-8 HCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)- (9CI) (CA INDEX NAME)



RN 150756-35-7 HCAPLUS

CN Acetic acid, [2-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 158966-92-8 HCAPLUS


CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

antihistamines. The invention also encompasses the administration of I in a nasal or oral spray. A capsule contained I 0.1, lactose 150, cellulose 50, and magnesium stearate 6 mg.

- ST allergic asthma treatment **descarboethoxyloratadine**
pharmaceutical capsule
- IT Asthma
(allergic, inhibitors; treatment of allergic asthma and other disorders with **descarboethoxyloratadine**)
- IT **Heart, disease**
(arrhythmia; treatment of allergic asthma and other disorders with **descarboethoxyloratadine**)
- IT Drug delivery systems
(capsules; treatment of allergic asthma and other disorders with **descarboethoxyloratadine**)
- IT Drug delivery systems
(nasal sprays; treatment of allergic asthma and other disorders with **descarboethoxyloratadine**)
- IT Drug delivery systems
(sprays, oral; treatment of allergic asthma and other disorders with **descarboethoxyloratadine**)
- IT Drug delivery systems
(tablets; treatment of allergic asthma and other disorders with **descarboethoxyloratadine**)
- IT **Antihistamines**
Decongestants
Neoplasm
(treatment of allergic asthma and other disorders with **descarboethoxyloratadine**)
- IT **Leukotriene antagonists**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of allergic asthma and other disorders with **descarboethoxyloratadine**)
- IT 73836-78-9, **Leukotriene d4**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; treatment of allergic asthma and other disorders with **descarboethoxyloratadine**)
- IT 80619-02-9, **5-Lipoxygenase**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; treatment of allergic asthma and other disorders with **descarboethoxyloratadine**)
- IT 100643-71-8, **Descarboethoxyloratadine**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of allergic asthma and other disorders with **descarboethoxyloratadine**)
- IT 9035-51-2, **Cytochrome p450**, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(treatment of allergic asthma and other disorders with **descarboethoxyloratadine**)
- RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
- RE
- (1) Aberg; US 5595997 A 1997 HCAPLUS
- (2) Piwinski; US 5089496 A 1992 HCAPLUS
- IT 100643-71-8, **Descarboethoxyloratadine**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of allergic asthma and other disorders with **descarboethoxyloratadine**)
- RN 100643-71-8 HCAPLUS

CN 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)- (9CI) (CA INDEX NAME)



=> d all tot

L94 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2003 ACS

AN 1998:719296 HCAPLUS

DN 129:347313

TI Topical nasal antiinflammatory **compositions**

IN Segal, Catherine A.

PA Warner-Lambert Co., USA

SO PCT Int. Appl., 13 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K045-06

ICS A61K031-57; A61K031-58; A61K031-135; A61K031-35; A61K031-245;

A61K031-09; A61K031-38; A61K031-195; A61K031-47; A61K031-445;

A61K031-55; A61K031-44; A61K031-615; A61K031-415

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9848839	A1	19981105	WO 1998-US6483	19980402 <--
	W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9868780	A1	19981124	AU 1998-68780	19980402 <--
	EP 979105	A1	20000216	EP 1998-914420	19980402 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9809022	A	20000801	BR 1998-9022	19980402 <--
	JP 2001524108	T2	20011127	JP 1998-546998	19980402 <--
PRAI	US 1997-44306P	P	19970430 <--		
	WO 1998-US6483	W	19980402 <--		

AB Topically applicable nasal **compsns.** comprise a therapeutically effective amt. of an antiinflammatory agent and a at least one agent selected from the group consisting of a vasoconstrictor, a neuramidinase inhibitor, a leukotriene inhibitor, an antihistamine, an antiallergic agent, an anticholinergic agent, an anesthetic and a mucolytic agent. The present **compsns.** are useful as nasal sprays and nose drops for the treatment of nasal and sinus conditions.

ST topical nasal antiinflammatory; vasoconstrictor topical nasal

antiinflammatory; antihistamine topical nasal antiinflammatory;
 antiallergic topical nasal antiinflammatory
 IT Drug delivery systems
 (nasal sprays; topical nasal antiinflammatory **compns.**)
 IT Drug delivery systems
 (nasal; topical nasal antiinflammatory **compns.**)
 IT Drug delivery systems
 Drug delivery systems
 (solns., nasal; topical nasal antiinflammatory **compns.**)
 IT Allergy inhibitors
 Anesthetics
 Anti-inflammatory agents
 Antihistamines
 Cholinergic antagonists
 Expectorants
 Humectants
 Vasoconstrictors
 (topical nasal antiinflammatory **compns.**)
 IT **Leukotriene antagonists**
 Polyoxyalkylenes, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (topical nasal antiinflammatory **compns.**)
 IT 9001-67-6, Neuraminidase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; topical nasal antiinflammatory **compns.**)
 IT 50-02-2, Dexamethasone 56-81-5, Glycerin, biological studies 57-55-6,
 Propylene glycol, biological studies 58-73-1, Diphenhydramine 59-42-7,
 Phenylephrine 76-25-5, Triamcinolone acetonide 93-14-1, Guaifenesin
 94-09-7, Benzocaine 113-92-8 140-65-8, Pramoxine 526-36-3,
 Xylometazoline 586-60-7, Dyclonine 616-91-1, Acetylcysteine
 835-31-4, Naphazoline 1491-59-4, Oxymetazoline 3964-81-6, Azatadine
 5534-09-8, Beclomethasone dipropionate 15826-37-6, Cromolyn sodium
 22254-24-6, Ipratropium bromide 25322-68-3, PEG 50679-08-8,
 Terfenadine 51333-22-3, Budesonide 58581-89-8, Azelastine
 60205-81-4, Ipratropium 68844-77-9, **Astemizole**
 69049-73-6, Nedocromil 75970-99-9, **Norastemizole**
 79516-68-0, Levocabastine 80474-14-2, Fluticasone propionate
 83799-24-0, **Fexofenadine** 83881-51-0,
 Cetirizine 83919-23-7, Mometasone furoate 107753-78-6,
 Zafirlukast 111406-87-2, Zileuton 139110-80-8, Zanamivir
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (topical nasal antiinflammatory **compns.**)

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE

- (1) Bayer Ag; WO 9709067 A 1997 HCAPLUS
- (2) Bollinger, F; US 3482015 A 1969
- (3) Center For Innovative Technology; WO 9309764 A 1993 HCAPLUS
- (4) McNeil-Ppc Inc; WO 9701337 A 1997 HCAPLUS
- (5) McNeil-Ppc Inc; WO 9701341 A 1997 HCAPLUS
- (6) Sekisui Chem Ind Co Ltd; JP 62153227 A 1987 HCAPLUS
- (7) Stevenson, N; US 4053628 A 1977 HCAPLUS
- (8) Sunshine; WO 8504589 A 1985 HCAPLUS
- (9) The Procter & Gamble Company; WO 9507103 A 1995 HCAPLUS
- (10) The Procter & Gamble Company; EP 0780127 A 1997 HCAPLUS

L94 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2003 ACS

AN 1997:812193 HCAPLUS

DN 128:80034

TI A nasal spray containing an intranasal steroid and an antihistamine

IN Koochaki, Patricia Elaine

PA Procter & Gamble Company, USA

SO PCT Int. Appl., 17 pp.

CODEN: PIXXD2

DT Patent
 LA English
 IC ICM A61K031-57
 ICS A61K031-56; A61K031-44; A61K031-445; A61K031-415; A61K031-57;
 A61K031-44; A61K031-57; A61K031-44; A61K031-445; A61K031-57;
 A61K031-44; A61K031-415

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9746243	A1	19971211	WO 1997-US9518	19970603 <--
	W: AU, BR, CA, CN, JP, MX				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9731537	A1	19980105	AU 1997-31537	19970603
	CN 1222852	A	19990714	CN 1997-195225	19970603
	BR 9709650	A	19990810	BR 1997-9650	19970603
	JP 11511758	T2	19991012	JP 1997-500771	19970603
	EP 954318	A1	19991110	EP 1997-926878	19970603
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
PRAI	US 1996-657506		19960604		
	WO 1997-US9518		19970603		

AB Pharmaceutical compns. for nasal administration comprise (a) a safe and effective amt. of a glucocorticoid selected from the group consisting of beclomethasone, flunisolide, fluticasone, memetasone, budesonide, pharmaceutically acceptable salts thereof and mixts. thereof; (b) a safe and effective amt. of a fast acting antihistamine selected from the group consisting of acrivastine, carbinoxamine, diphenhydramine, chlorpheniramine, brompheniramine, dexchlorpheniramine, doxylamine, clemastine, promethazine, trimeprazine, methdilazine, hydroxyzine, pyrilamine, rocastine, tripeleminamine, meclizine, triprolidine, azatadine, cyproheptadine, phenindamine, pharmaceutically acceptable salts thereof and mixts. thereof; and (c) an aq., intranasal carrier wherein the compn. is free of capsaicin and, preferably, free of powders or granules. The present invention also relates to a method for the treatment of symptoms assocd. with seasonal or perennial allergic rhinitis comprising the administration of a safe and effective amt. of the intranasal pharmaceutical compns. of the present invention. A nasal spray contained beclomethasone dipropionate monohydrate 0.042, chlorpheniramine 0.500, Avicel RC-591 1.200, dextrose 5.100, Polysorbate 80 0.050, benzalkonium chloride 0.020, phenylethyl alc. 0.025, and water q.s. 100%.

ST nasal pharmaceutical spray steroid antihistamine; beclomethasone chlorpheniramine nasal pharmaceutical spray

IT **Nose**
 (allergic rhinitis, perennial; nasal spray contg. intranasal steroid and antihistamine)

IT Adrenoceptor agonists

Antihistamines

Glucocorticoids

Steroids, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nasal spray contg. intranasal steroid and antihistamine)

IT Drug delivery systems

Drug delivery systems

(nasal sprays; nasal spray contg. intranasal steroid and antihistamine)

IT Analgesics

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(non-opiate; nasal spray contg. intranasal steroid and antihistamine)

IT Anti-inflammatory agents

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nonsteroidal; nasal spray contg. intranasal steroid and antihistamine)

IT 9029-60-1, Lipoxigenase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibitors; nasal spray contg. intranasal steroid and antihistamine)

IT 58-73-1, Diphenhydramine 59-33-6 59-42-7, Phenylephrine 60-87-7, Promethazine 68-88-2, Hydroxyzine 76-25-5, Triamcinolone acetoneide 84-22-0, Tetrahydrozoline 84-96-8, Trimeprazine 86-22-6, Brompheniramine 90-82-4, Pseudoephedrine 91-81-6, Tripelennamine 113-92-8 129-03-3, Cyproheptadine 486-12-4, Triprolidine 486-16-8, Carbinoxamine 562-10-7 569-59-5 569-65-3, Meclizine 835-31-4, Naphazoline 1082-57-1, Tramazoline 1491-59-4, Oxymetazoline 1982-37-2, Methdilazine 3385-03-3, Flunisolide 3964-81-6, Azatadine 4419-39-0, Beclomethasone 14838-15-4, Phenylpropanolamine 15686-51-8, Clemastine 25523-97-1, Dexchlorpheniramine 29216-28-2, Mequitazine 34580-13-7, Ketotifen 50679-08-8, Terfenadine 51333-22-3, Budesonide 53882-12-5, Lodoxamide 58581-89-8, Azelastine 60607-34-3, Oxatomide 64294-95-7, Setastine 68844-77-9, **Astemizole** 77011-63-3, Beclomethasone dipropionate monohydrate 79516-68-0, Levocabastine 79712-55-3, Tazifylline 79794-75-5, Loratadine 83881-51-0, **Cetirizine** 86181-42-2, Temelastine 87848-99-5, Acrivastine 90566-53-3, Fluticasone 90729-43-4, **Ebastine** 91833-77-1, Rocastine 121807-05-4, Acrivastine hydrochloride
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nasal spray contg. intranasal steroid and antihistamine)

L94 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2003 ACS

AN 1997:542332 HCAPLUS

DN 127:210367

TI Pharmaceutical **compositions** containing a leukotriene inhibitor and loratadine for treatment of asthma, allergy, and inflammation

IN Dahlen, Sven-Erik; Scolnick, Edward M.

PA Merck & Co., Inc., USA; Dahlen, Sven-Erik; Scolnick, Edward M.

SO PCT Int. Appl., 10 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-41

ICS A61K031-44; A61K031-47; A61K031-405

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9728797	A1	19970814	WO 1997-US1799	19970204 <--
	W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	CA 2245162	AA	19970814	CA 1997-2245162	19970204 <--
	AU 9722579	A1	19970828	AU 1997-22579	19970204 <--
	AU 732671	B2	20010426		
	CN 1210465	A	19990310	CN 1997-192149	19970204 <--
	JP 11504044	T2	19990406	JP 1997-528627	19970204 <--
	BR 9707369	A	19990720	BR 1997-7369	19970204 <--
	EP 1014972	A1	20000705	EP 1997-905757	19970204 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO			
	NO 9803641	A	19980807	NO 1998-3641	19980807 <--
PRAI	US 1996-11328P	P	19960208		<--
	GB 1996-8927	A	19960429		<--
	WO 1997-US1799	W	19970204		<--
AB	A method of treating asthma, allergy and inflammation comprises treatment with a leukotriene inhibitor and loratadine either				

concurrently in sep. doses or combined in a single pharmaceutical formulation. A film coated tablet contained montelukast sodium 10.4, loratadine 10.0, microcryst. cellulose 66.6, lactose monohydrate 100.0, croscarmellose sodium 6.0, and magnesium stearate in the core and hydroxypropyl methylcellulose 2.25, hydroxypropyl cellulose 1.25, and titanium dioxide 1.50 in the film coating.

ST pharmaceutical leukotriene inhibitor loratadine asthma allergy;
inflammation pharmaceutical leukotriene inhibitor loratadine asthma

IT Leukotrienes
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; pharmaceutical compns. contg. leukotriene inhibitor and loratadine for treatment of asthma, allergy, and inflammation)

IT Drug delivery systems
(oral; pharmaceutical compns. contg. leukotriene inhibitor and loratadine for treatment of asthma, allergy, and inflammation)

IT Allergy inhibitors
Anti-inflammatory agents
Antiasthmatics
(pharmaceutical compns. contg. leukotriene inhibitor and loratadine for treatment of asthma, allergy, and inflammation)

IT 79794-75-5, Loratadine 103177-37-3, Pranlukast 107753-78-6, Zafirlukast 151767-02-1, Montelukast sodium 152922-64-0 159082-78-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. contg. leukotriene inhibitor and loratadine for treatment of asthma, allergy, and inflammation)

L94 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2003 ACS
AN 1997:496788 HCAPLUS
DN 127:113353
TI A nasal spray containing a steroid and a antihistamine
IN Cramer, Ronald Dean
PA The Procter and Gamble Company, USA
SO Eur. Pat. Appl., 9 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM A61K031-57
ICS A61K031-58; A61K031-56; A61K031-495; A61K031-445; A61K031-55
ICI A61K031-56, A61K031-495; A61K031-56, A61K031-445; A61K031-56, A61K031-55; A61K031-57, A61K031-495; A61K031-57, A61K031-445; A61K031-57, A61K031-55; A61K031-58, A61K031-495
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 780127	A1	19970625	EP 1996-308852	19961205 <--
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 1995-574791		19951219 <--		

AB Novel nasal spray compns. comprising a safe and effective amt. of a glucocorticosteroid and and antihistamine possessing leukotriene inhibiting properties are claimed. A nasal spray contained beclomethasone dipropionate.H2O 0.042, loratadine 0.200, Avicel RC-591 1.200, dextrose 5.100, Polysorbate-80 0.025, benzalkonium chloride 0.040, phenylethyl alc. 0.250, and distd. water q.s. 100%.

ST nasal spray steroid antihistamine; beclomethasone loratadine nasal spray
IT Allergy inhibitors

Antihistamines**Expectorants**

(nasal spray contg. steroid and antihistamine)

IT Glucocorticoids

Leukotriene antagonists

Steroids, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nasal spray contg. steroid and antihistamine)

IT Drug delivery systems

Drug delivery systems

(nasal sprays; nasal spray contg. steroid and antihistamine)

IT Analgesics

(non-opiate; nasal spray contg. steroid and antihistamine)

IT Anti-inflammatory agents

(nonsteroidal; nasal spray contg. steroid and antihistamine)

IT 9029-60-1, Lipoxxygenase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibitors; nasal spray contg. steroid and antihistamine)

IT 59-42-7, Phenylephrine 76-25-5, Triamcinolone acetonide 84-22-0, Tetrahydrozoline 90-82-4, Pseudoephedrine 101-40-6, Propylhexedrine 124-94-7, Triamcinolone 526-36-3, Xylometazoline 835-31-4, Naphazoline 1082-57-1, Tramazoline 1491-59-4, Oxymetazoline 3385-03-3, Flunisolide 4419-39-0, Beclomethasone 7632-10-2 14838-15-4, Phenylpropanolamine 51333-22-3, Budesonide 58581-89-8, Azelastine 77011-63-3, Beclomethasone dipropionate monohydrate 79307-93-0, Azelastine hydrochloride 79794-75-5, Loratadine 83881-51-0, Cetirizine 90566-53-3, Fluticasone 105102-22-5, Mometasone 177843-18-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nasal spray contg. steroid and antihistamine)

L94 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2003 ACS

AN 1995:464437 HCAPLUS

Correction of: 1993:670812

DN 122:213760

Correction of: 119:270812

TI Preparation of benzamidines and analogs as LTB4 antagonists

IN Anderskewitz, Ralf; Schromm, Kurt; Renth, Ernst Otto; Himmelsbach, Frank; Birke, Franz; Fuegner, Arnim

PA Boehringer Ingelheim KG, Germany

SO Ger. Offen., 24 pp.

CODEN: GWXXBX

DT Patent

LA German

IC ICM C07C257-18

ICS C07C311-29; C07C323-20; C07C317-22; A61K031-155; C07D311-74;

C07D307-79; C07D213-81; C07D267-06; C07D267-22; A61K031-335;

A61K031-44

ICI C07D405-12, C07D213-81, C07D315-00, C07D325-00; C07D409-12, C07D333-38, C07D315-00, C07D325-00


CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)

Section cross-reference(s): 1

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4203201	A1	19930812	DE 1992-4203201	19920205 <--
	WO 9316036	A1	19930819	WO 1993-EP70	19930114
	W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, PL, RU, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

AU 9333497	A1	19930903	AU 1993-33497	19930114
AU 673343	B2	19961107		
EP 625138	A1	19941123	EP 1993-902195	19930114
EP 625138	B1	19990602		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 07503718	T2	19950420	JP 1993-513701	19930114
HU 68419	A2	19950628	HU 1994-2291	19930114
HU 216191	B	19990528		
PL 173789	B1	19980430	PL 1993-304713	19930114
PL 173781	B1	19980430	PL 1993-316750	19930114
RU 2124002	C1	19981227	RU 1994-41836	19930114
EP 902013	A1	19990317	EP 1998-121305	19930114
EP 902013	B1	20011212		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
AT 180770	E	19990615	AT 1993-902195	19930114
ES 2132216	T3	19990816	ES 1993-902195	19930114
SK 281016	B6	20001009	SK 1994-914	19930114
CZ 287209	B6	20001011	CZ 1994-1886	19930114
AT 210634	E	20011215	AT 1998-121305	19930114
ES 2165122	T3	20020301	ES 1998-121305	19930114
JP 2002322143	A2	20021108	JP 2002-73593	19930114
ZA 9300733	A	19930806	ZA 1993-733	19930203
FI 9403618	A	19940804	FI 1994-3618	19940804
NO 9402903	A	19941003	NO 1994-2903	19940804
US 6037377	A	20000314	US 1995-460961	19950605
CZ 287173	B6	20001011	CZ 1997-1203	19970418
US 6489365	B1	20021203	US 2000-484073	20000118
PRAI DE 1992-4203201	A	19920205		
DE 1992-4224289	A	19920723		
DE 1992-4244241	A	19921224		
EP 1993-902195	A3	19930114		
JP 1993-513701	A3	19930114		
WO 1993-EP70	A	19930114		
US 1993-129154	B1	19931122		
US 1994-352003	B1	19941208		
US 1995-460961	A1	19950605		
US 1997-779869	B1	19970106		
OS MARPAT 122:213760				
GI				



AB Title compds I [A = Z1-A1-Z2, etc.; A1 = alkylene, CH:CH, bis(methylene), etc.; R = (substituted) Ph; R4 = H, halo, alkyl, aryl, etc.; Z = CH:CH, CH:N, 1,2-phenylene; Z1 = O, NH, CO, CH2, etc.; Z2 = O, NH, S] were prepd. Thus, 4-AcC6H4OH was stirred 20 h with 4-(BrCH2)C6H4CN in CHCl3 contg. EtOH and HCl and the product imido ester was treated with EtOH/NH3 to give title compd. II as the hydrochloride. II had IC50 of 0.05-0.5 .mu.M against LTB4-induced neutrophil aggregation.

ST benzamidine LTB4 antagonist prepn; antiinflammatory benzamidine prepn;

antiallergic benzamidine prepn
 IT Allergy inhibitors
 Bronchodilators
 Inflammation inhibitors
 (prepn. of benzamidines as LTB4 antagonists)
 IT Psoriasis
 (treatment; prepn. of benzamidines as LTB4 antagonists)
 IT Intestine, disease
 (ulcerative colitis, treatment; prepn. of benzamidines as LTB4 antagonists)
 IT 151027-01-9P 151027-02-0P 151027-03-1P 151027-04-2P 151027-05-3P
 151027-06-4P 151027-07-5P 151027-08-6P 151027-09-7P 151027-10-0P
 151027-11-1P 151027-12-2P 151027-13-3P 151027-14-4P 151027-15-5P
 151027-16-6P 151027-17-7P 151027-18-8P 151027-19-9P 151027-20-2P
 151027-21-3P 151027-22-4P 151027-23-5P 151027-24-6P 151027-25-7P
 151027-26-8P 151027-27-9P 151027-28-0P 151027-29-1P 151027-30-4P
 151027-31-5P 151027-32-6P 151027-33-7P 151027-34-8P 151027-35-9P
 151027-36-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of benzamidines as LTB4 antagonists)
 IT 71160-24-2
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (prepn. of benzamidines as LTB4 antagonists)
 IT 99-93-4 17201-43-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of benzamidines as LTB4 antagonists)
 IT 151027-37-1P 151027-38-2P 151027-39-3P 151027-40-6P 151027-41-7P
 151027-42-8P 151027-43-9P 151027-44-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of benzamidines as LTB4 antagonists)

L94 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2003 ACS
 AN 1994:134309 HCAPLUS
 DN 120:134309
 TI Quinoline derivatives as leukotriene antagonists
 IN Zamboni, Robert; Guay, Daniel; Labelle, Marc
 PA Merck Frosst Canada Inc., Can.
 SO Eur. Pat. Appl., 14 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 IC ICM C07D215-18
 ICS A61K031-47
 CC 27-17 (Heterocyclic Compounds (One Hetero Atom))
 Section cross-reference(s): 63


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 565185	A1	19931013	EP 1993-200973	19930402 <--
	EP 565185	B1	19980708		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 5270324	A	19931214	US 1992-866690	19920410
	CN 1080169	A	19940105	CN 1992-105948	19920616
	CA 2092896	AA	19931011	CA 1993-2092896	19930329
	AT 168100	E	19980715	AT 1993-200973	19930402
	ES 2117691	T3	19980816	ES 1993-200973	19930402
	AU 9336863	A1	19931014	AU 1993-36863	19930408
	AU 653476	B2	19940929		
	WO 9321159	A1	19931028	WO 1993-CA156	19930408
	W: BB, BG, BR, CZ, FI, HU, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO,				

RU, SD, SK, UA, US
 RW: BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

ZA 9302533	A	19931104	ZA 1993-2533	19930408
HU 70399	A2	19951030	HU 1994-2905	19930408
HU 218917	B	20001228		
RU 2143426	C1	19991227	RU 1994-45911	19930408
RO 115954	B1	20000830	RO 1994-1618	19930408
JP 06025173	A2	19940201	JP 1993-83482	19930409
JP 2504687	B2	19960605		
CN 1083052	A	19940302	CN 1993-105948	19930409
CN 1043761	B	19990623		
ES 2080656	B1	19961016	ES 1993-1617	19930719
ES 2080656	A1	19960201		
FI 9404734	A	19941007	FI 1994-4734	19941007
NO 9403792	A	19941208	NO 1994-3792	19941007
LV 12290	B	19991120	LV 1999-68	19990426
PRAI US 1992-866690	A	19920410		
WO 1993-CA156	W	19930408		

GI



- AB The title compds. I (R1 = 6-F or 6,7-difluoro), useful in the treatment of asthma (no data), inflammatory diseases of the eye (no data), etc., are prepd. and I-contg. formulations presented. Thus, I (R1 = 6,7-difluoro) was prepd. from 3,4-difluoroaniline in 12 steps.
- ST quinoline prepn leukotriene antagonist; asthma treatment prepn quinoline; antiasthmatic prepn quinoline leukotriene antagonist
- IT **Leukotrienes**
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (antagonists of, quinoline derivs. as)
- IT Inflammation inhibitors
 (leukotriene antagonist quinoline derivs.)
- IT Asthma
 (treatment of, antiinflammatory quinoline deriv. leukotriene antagonists for)
- IT Bronchodilators
 (antiasthmatics, leukotriene antagonist quinoline derivs.)
- IT Eye, disease
 (uveitis, treatment of, antiinflammatory quinoline deriv. leukotriene antagonists for)
- IT 152922-64-0P 152952-63-1P 152952-64-2P 152952-65-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and leukotriene antagonists activity)
- IT 89729-09-9P 152922-65-1P, 6,7-Difluoro-2-methylquinoline 152922-66-2P
 152922-67-3P 152922-68-4P 152922-69-5P 152922-70-8P 152922-71-9P
 152922-72-0P, 1-Acetylthiomethylcyclopropaneacetonitrile 152922-73-1P
 152922-74-2P 152922-86-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and reaction of, in prepn. of leukotriene antagonists)
- IT 1559-02-0, Diethyl-1,1-cyclopropanedicarboxylate

RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, in prepn. of leukotriene antagonists derivs.)
 IT 118-75-2, reactions 1128-61-6, 6-Fluoro-2-methylquinoline 3863-11-4,
 3,4-Difluoroaniline 4170-30-3, 2-Butenal
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, in prepn. of leukotriene-antagonists quinoline derivs.)

L94 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2003 ACS

AN 1994:77038 HCAPLUS

DN 120:77038

TI Novel amidine derivatives, their preparation, and their use as medicaments
 with LTB4-antagonistic effect

IN Anderskewitz, Ralf; Schromm, Kurt; Renth, Ernst Otto; Himmelsbach, Frank;
 Birke, Franz; Fuegner, Armin

PA Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim
 K.-G.

SO PCT Int. Appl., 52 pp.

CODEN: F1XXD2

DT Patent

LA German

IC ICM C07C257-18



ICS A61K031-155; C07D311-22; C07D213-78; A61K031-35; A61K031-44

CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)

Section cross-reference(s): 1

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9316036	A1	19930819	WO 1993-EP70	19930114
	W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, PL, RU, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	DE 4203201	A1	19930812	DE 1992-4203201	19920205 <--
	DE 4224289	A1	19940127	DE 1992-4224289	19920723
	DE 4244241	A1	19940630	DE 1992-4244241	19921224
	AU 9333497	A1	19930903	AU 1993-33497	19930114
	AU 673343	B2	19961107		
	EP 625138	A1	19941123	EP 1993-902195	19930114
	EP 625138	B1	19990602		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 07503718	T2	19950420	JP 1993-513701	19930114
	PL 173789	B1	19980430	PL 1993-304713	19930114
	PL 173781	B1	19980430	PL 1993-316750	19930114
	PL 173780	B1	19980430	PL 1993-316751	19930114
	SK 281016	B6	20001009	SK 1994-914	19930114
	FI 9403618	A	19940804	FI 1994-3618	19940804
	NO 9402903	A	19941003	NO 1994-2903	19940804
	FI 2000002501	A	20001115	FI 2000-2501	20001115
PRAI	DE 1992-4203201	A	19920205		
	DE 1992-4224289	A	19920723		
	DE 1992-4244241	A	19921224		
	WO 1993-EP70	A	19930114		
OS	MARPAT 120:77038				
GI					



AB Amidines I [R1, R2, R3 = wide variety of groups; or adjacent R1R2 = (un)substituted CH:CHCH:CH, OCH2CH2, OCH2O, OCH2CH2O, (CH2)3-4, NHCO2, NHCOCH2O, COCH2O, COCH2CH2O; R4 = halo, (di)(alkyl)amino, OH, alkoxy; A = X1A1X2, X2A2X3, X4A2X2, OC6H4O, 1,4-piperazinediyl (Q), etc.; B = CH:CH, CH:N, S, o-C6H4; A1 = C2-4 alkylene, CH2CH:CHCH2, CH2C.tplbond.CCH2, Q1, CH2Q1CH2, (Q1 = cyclohexanediyl), etc.; A2 = C1-5 alkylene; X1 = O, NH, S, SO, SO2, CO, CH2, Q; X2 = O, NH, S, OC6H4; X3 = NHCO, CONH, SO2NH, Q; X4 = NHCO, CONH, NHSO2, SO2NH, NHCONH] and their salts were prepd. as LTB4 antagonists, for treatment of inflammatory and/or allergic conditions. For example, 4-[(4-acetyl-2-isopropyl-5-methylphenoxy)butyloxy]benzonitrile underwent Pinner reaction (i.e., HCl in EtOH to give the imidate ester hydrochloride, and subsequent ammonolysis of this with 5M NH3 in EtOH) to give amidine salt II-HCl. Several tested I inhibited binding of [3H]-LTB4 to live U937 cell receptors (Ki = 1.7-15.0 nM), inhibited LTB4-induced guinea-pig neutrophil aggregation in vitro (EC50 = 0.02-1.9 .mu.M), and inhibited LTB4-induced neutrophil accumulation in ears of mice (p.o. ED50 = 0.8-3.8 mg/kg).

ST amidine phenoxyalkoxyphenyl prepn LTB4 antagonist; leukotriene B4 antagonist amidine prepn; antiallergic amidine prepn; antiinflammatory amidine prepn

IT **Psoriasis**

(amidine LTB4 antagonists for treatment of)

IT Allergy inhibitors

Inflammation inhibitors

Ulcer inhibitors

(amidine antagonists of LTB4)

IT **Leukotrienes**

RL: RCT (Reactant); RACT (Reactant or reagent)

(antagonists, amidines)

IT Bronchodilators

(antiasthmatics, amidine antagonists of LTB4)

IT Amidines

RL: SPN (Synthetic preparation); PREP (Preparation)

(aryl, prepn. as antagonists of LTB4)

IT Intestine, disease

(ulcerative colitis, amidine LTB4 antagonists for treatment of)

IT 151027-40-6P 151027-42-8P 152092-86-9P 152092-87-0P

RL: SPN (Synthetic preparation); PREP (Preparation)

(Pinner reaction in prepn. of LTB4 antagonist)

IT 71160-24-2, LTB4

RL: RCT (Reactant); RACT (Reactant or reagent)

(amidine antagonists of)

IT 3524-86-5P, 4-(4-Bromobutoxy)acetophenone 49787-00-0P,
4-Hydroxybenzamidoxime 151027-43-9P, 4-Acetyl-3-methoxy-2-propylphenol
151027-44-0P, 4-(4-Bromobutylthio)benzamidine
RL: SPN (Synthetic preparation); PREP (Preparation)
(etherification in prepn. of LTB4 antagonists)

IT 151027-41-7P 152092-84-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and ammonolysis in prepn. of LTB4 antagonist)

IT 152092-85-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and hydrogenation in prepn. of LTB4 antagonist)

IT 151027-03-1 151027-04-2 151027-05-3 151027-06-4 151027-07-5
151027-08-6 151027-10-0 151027-11-1 151027-12-2 151027-13-3
151027-14-4 151027-15-5 151027-16-6 151027-17-7 151027-18-8
151027-19-9 151027-20-2 151027-21-3 151027-22-4 151027-23-5
151027-24-6 151027-25-7 151027-26-8 151027-27-9 151027-28-0
151027-29-1 151027-30-4 151027-32-6 151027-33-7 151027-34-8
151027-35-9 151027-36-0 152092-63-2 152092-64-3 152092-65-4
152092-66-5 152092-67-6 152092-68-7 152092-69-8 152092-70-1
152092-71-2 152092-72-3 152092-73-4 152092-74-5 152092-75-6
152092-76-7 152092-77-8 152092-78-9 152092-79-0 152092-80-3
152092-81-4 152092-82-5 152092-83-6 152509-27-8 152509-29-0
152510-57-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. as LTB4 antagonist)

L94 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2003 ACS

AN 1993:225676 HCAPLUS

DN 118:225676

TI Leukotriene receptor antagonist-antihistamine complex for treatment of
hypersensitivity diseases

IN Ambrus, Gyorgy Ferenc; Himmelstein, Kenneth James; Woodward, David
Frederick

PA Allergan, Inc., USA

SO PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-44

ICS A61K031-19; A61K045-06

CC 1-7 (Pharmacology)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9303723	A1	19930304	WO 1992-US6559	19920806 <--
	W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP,				
	KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF,				
	BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	US 5276044	A	19940104	US 1991-745232	19910814 <--
	AU 9224270	A1	19930316	AU 1992-24270	19920806 <--
	AU 658221	B2	19950406		
	EP 599943	A1	19940608	EP 1992-917850	19920806 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
PRAI	US 1991-745232		19910814	<--	
	WO 1992-US6559		19920806	<--	

OS MARPAT 118:225676

AB Acid-base complexes of leukotriene receptor antagonists with
antihistaminics are nonirritant drugs for the treatment of
hypersensitivity diseases, e.g. asthma, hay fever and allergic
conjunctivitis. A complex was prepd. by reacting di-Na
2(S)-hydroxy-3(R)-[(2-carboxyethyl)thiol-3-[2-(8-

phenyloctyl)phenyl]propionate with pyrillamine-HCl in aq. soln. at pH 7.4. Pretreatment with the complex decreased the conjunctival microvascular permeability in the eye of guinea pigs treated with histamine and the leukotriene mediator LTD4.

- ST hypersensitivity disease leukotriene receptor antagonist antihistaminic
 IT Allergy inhibitors
 (complexes of antihistaminics with leukotriene receptor antagonists as, for treatment of hypersensitivity diseases)
 IT **Antihistaminics**
 (complexes with leukotriene receptor antagonists, hypersensitivity diseases treatment by)
 IT **Leukotrienes**
 RL: BIOL (Biological study)
 (antagonists, complexes, with antihistaminics, hypersensitivity diseases treatment by)
 IT 58-73-1D, Diphenhydramine, complexes with leukotriene receptor antagonists
 60-87-7D, Promethazine, complexes with leukotriene receptor antagonists
 82-88-2D, complexes with leukotriene receptor antagonists 82-92-8D,
 Cyclizine, complexes with leukotriene receptor antagonists 82-93-9D,
 Chlorcyclizine, complexes with leukotriene receptor antagonists
 86-21-5D, Pheniramine, complexes with leukotriene receptor antagonists
 91-81-6D, Tripeleminamine, complexes with leukotriene receptor antagonists
 91-82-7D, Pyrrobutamine, complexes with leukotriene receptor antagonists
 91-84-9D, complexes with leukotriene receptor antagonists 113-92-8D,
 complexes with leukotriene receptor antagonists 147-20-6D,
 Diphenylpyraline, complexes with leukotriene receptor antagonists
 486-12-4D, Triprolidine, complexes with leukotriene receptor antagonists
 522-24-7D, Fenethazine, complexes with leukotriene receptor antagonists
 RL: BIOL (Biological study)
 (hypersensitivity diseases treatment by)
 IT 147492-90-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, for treatment of hypersensitivity diseases)

=> fil embase

FILE 'EMBASE' ENTERED AT 14:26:10 ON 09 MAR 2003

COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE COVERS 1974 TO 6 Mar 2003 (20030306/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d 1109 all tot

L109 ANSWER 1 OF 5 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

AN 2000397741 EMBASE

TI Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma.

AU Wilson A.M.; Orr L.C.; Sims E.J.; Dempsey O.J.; Lipworth B.J.

CS Prof. B.J. Lipworth, Asthma and Allergy Research Group, Ninewells Hospital/Medical School, University of Dundee, Dundee DD1 9SY, United Kingdom

SO American Journal of Respiratory and Critical Care Medicine, (2000) 162/4 I (1297-1301).

Refs: 35

ISSN: 1073-449X CODEN: AJCMED

CY United States

DT Journal; Article

FS 015 Chest Diseases, Thoracic Surgery and Tuberculosis

026 Immunology, Serology and Transplantation
 030 Pharmacology
 037 Drug Literature Index

LA English

SL English

AB To compare the antiasthmatic efficacy of inflammatory mediator blockade versus topical corticosteroid therapy in patients with seasonal allergic rhinitis (SAR) and asthma, 14 patients were enrolled into a single-blind, double-dummy, placebo-controlled crossover study comparing 2 wk therapy of (1) 400 .mu.g orally inhaled budesonide plus 200 .mu.g intranasal budesonide (BUD) or (2) 10 mg oral montelukast plus 10 mg oral cetirizine (ML + CZ). Before each treatment period, patients received 7 to 10 d placebo washout. All treatments were given once daily in the morning. Throughout the study, patients recorded the following domiciliary measures: peak expiratory flow (PEF), rescue inhaler requirement, asthma symptoms, and daily activity score. Laboratory measurements were made at trough of adenosine monophosphate (AMP) bronchial challenge and exhaled nitric oxide (NO). Compared with pooled placebo (PL), there were significant ($p < 0.05$) improvements in all domiciliary measures with both treatments (mean PEF [L/min] PL: 463; BUD: 478; ML + CZ: 483). For geometric mean AMP PC20 (mg/ml), there was an improvement ($p < 0.05$), compared with PL (47), for ML + CZ (133) but not for BUD (51); whereas for NO (ppb) there was significant suppression with BUD (7.6) but not ML + CZ (11.5) compared with PL (13.6). In conclusion, both combined mediator blockade and combined topical corticosteroids are equally effective antiasthma therapy in patients with asthma and SAR.

CT Medical Descriptors:

*allergic rhinitis: DT, drug therapy

*asthma: DT, drug therapy

mediator release

peak expiratory flow

inhaler

human

clinical trial

double blind procedure

single blind procedure

crossover procedure

controlled study

article

priority journal

Drug Descriptors:

*corticosteroid: CT, clinical trial

*corticosteroid: AD, drug administration

*corticosteroid: CM, drug comparison

*corticosteroid: DT, drug therapy

*corticosteroid: NA, intranasal drug administration

*corticosteroid: TP, topical drug administration

*budesonide: CT, clinical trial

*budesonide: AD, drug administration

*budesonide: CM, drug comparison

*budesonide: DO, drug dose

*budesonide: DT, drug therapy

*budesonide: IH, inhalational drug administration

*budesonide: NA, intranasal drug administration

*cetirizine: CT, clinical trial

*cetirizine: CB, drug combination

*cetirizine: CM, drug comparison

*cetirizine: DT, drug therapy

*montelukast: CT, clinical trial

*montelukast: CB, drug combination

*montelukast: CM, drug comparison

*montelukast: DT, drug therapy

adenosine phosphate

nitric oxide: EC, endogenous compound

RN (budesonide) 51333-22-3; (cetirizine) 83881-51-0, 83881-52-1; (montelukast) 151767-02-1, 158966-92-8; (adenosine phosphate) 61-19-8, 8063-98-7; (nitric oxide) 10102-43-9

CN (1) Pulmicort turbuhaler; (2) Rhinocort; (3) Singulair; (4) Zirtek

CO (2) Astra (United Kingdom); (3) Merck Sharp and Dohme; (4) UCB

L109 ANSWER 2 OF 5 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

AN 2000332735 EMBASE

TI **Montelukast**, a leukotriene receptor antagonist, in combination with **loratadine**, a histamine receptor antagonist, in the treatment of chronic asthma.

AU Reicin A.; White R.; Weinstein S.F.; Finn A.F. Jr.; Nguyen H.; Peszek I.; Geissler L.; Seidenberg B.C.

CS Dr. A. Reicin, Pulmonary/Immunology, Merck Research Laboratories, RY32-649, PO Box 2000, Rahway, NJ 07065, United States

SO Archives of Internal Medicine, (11 Sep 2000) 160/16 (2481-2488).
Refs: 45
ISSN: 0003-9926 CODEN: AIMDAP

CY United States

DT Journal; Article

FS 006 Internal Medicine
015 Chest Diseases, Thoracic Surgery and Tuberculosis
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles

LA English

SL English

AB Background: **Montelukast** sodium, a potent, oral, specific leukotriene-receptor antagonist, has demonstrated clinical efficacy in the treatment of chronic asthma. **Loratadine**, a selective histamine type 1 (H1)-receptor antagonist, has demonstrated antiallergic properties. Leukotriene-receptor antagonists given concomitantly with H1-receptor antagonists have been shown to have additive effects in the prevention of bronchospasm in antigen-challenge models. Objective: To determine whether **montelukast** plus **loratadine** provides improved efficacy to **montelukast** alone in the treatment of chronic asthma. Methods: The efficacy of **montelukast** alone vs **montelukast-loratadine** was studied in a 10-week, multicenter, randomized, double-blind, 2 x 2 crossover study. After a 2-week placebo run-in period, patients received **montelukast** sodium (10 mg) plus **loratadine** (20 mg), or **montelukast** sodium (10 mg) plus placebo once daily for 2 weeks. After a 2-week placebo washout period, patients were crossed over to receive 2 weeks of the other active treatment regimen, followed by another 2-week placebo washout period. Results: **Montelukast** given concomitantly with **loratadine** caused significant improvement in percentage of change from baseline in forced expiratory volume in 1 second (FEV1) compared with **montelukast** alone (13.86% vs 9.72%; P=.001). The average additional effect of **loratadine** (least square mean difference in percentage of change from baseline in FEV1) was 4.15% (95% confidence interval, 1.65%-6.65%). Key secondary end points (mean daily .beta.-agonist use, daytime and nighttime symptom scores, morning and evening peak expiratory flow rate, and the Patient Global Evaluation) all showed significant improvement with **montelukast-loratadine** (P<.05). Conclusion: **Montelukast-loratadine** significantly improved end points of asthma control during a 2-week treatment period.

CT Medical Descriptors:
*asthma: DI, diagnosis
*asthma: DT, drug therapy
drug efficacy
forced expiratory volume

drug safety
 headache: SI, side effect
 dyspepsia: SI, side effect
 human
 male
 female
 major clinical study
 clinical trial
 randomized controlled trial
 double blind procedure
 crossover procedure
 multicenter study
 controlled study
 adolescent
 adult
 article
 priority journal
 Drug Descriptors:

*montelukast: AE, adverse drug reaction
 *montelukast: CT, clinical trial
 *montelukast: AD, drug administration
 *montelukast: CB, drug combination
 *montelukast: DO, drug dose
 *montelukast: DT, drug therapy
 *montelukast: PO, oral drug administration
 *loratadine: AE, adverse drug reaction
 *loratadine: CT, clinical trial
 *loratadine: CB, drug combination
 *loratadine: DO, drug dose
 *loratadine: DT, drug therapy

antihistaminic agent: AE, adverse drug reaction
 antihistaminic agent: CT, clinical trial
 antihistaminic agent: CB, drug combination
 antihistaminic agent: DO, drug dose
 antihistaminic agent: DT, drug therapy
 leukotriene receptor blocking agent: AE, adverse drug reaction
 leukotriene receptor blocking agent: CT, clinical trial
 leukotriene receptor blocking agent: AD, drug administration
 leukotriene receptor blocking agent: CB, drug combination
 leukotriene receptor blocking agent: DO, drug dose
 leukotriene receptor blocking agent: DT, drug therapy
 leukotriene receptor blocking agent: PO, oral drug administration

RN (montelukast) 151767-02-1, 158966-92-8; (
 loratadine) 79794-75-5
 CN Singulair

L109 ANSWER 3 OF 5 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

AN 2000197224 EMBASE

TI Evaluation of treatment response in patients with seasonal allergic rhinitis using domiciliary nasal peak inspiratory flow.

AU Wilson A.; Dempsey O.J.; Sims E.J.; Coutie W.J.R.; Paterson M.C.; Lipworth B.J.

CS Prof. B.J. Lipworth, Allergy and Respiratory Medicine, Dept. of Clinic. Pharmacol./Therap., Ninewells Hosp. and Medical School, Dundee DD1 9SY, United Kingdom

SO Clinical and Experimental Allergy, (2000) 30/6 (833-838).
 Refs: 18

ISSN: 0954-7894 CODEN: CLEAEN

CY United Kingdom

DT Journal; Article

FS 011 Otorhinolaryngology

026 Immunology, Serology and Transplantation

027 Biophysics, Bioengineering and Medical Instrumentation

037 Drug Literature Index

LA English

SL English

AB Background: Measurement of domiciliary nasal peak inspiratory flow rate (PIFR) may have a role in the objective assessment of treatment response in seasonal allergic rhinitis (SAR). Objective: We wished to evaluate the relationship between domiciliary measurement of nasal PIFR and a variety of symptoms associated with rhinitis. Methods Thirty-eight nonasthmatic patients, mean age (SEM) 30 years (1.4), with symptomatic SAR were evaluated in a placebo-controlled, single-blind, double-dummy, three way parallel group study. Patients received oral **cetirizine** 10 mg once daily and were randomized to receive, in addition, either: (i) intranasal mometasone furoate 200 .mu.g (n=14); (ii) oral **montelukast** 10 mg (n=11); or (iii) placebo (n=13). All treatments were given once daily for 4 weeks and were preceded by a 1 week placebo period. Domiciliary diary cards were used to record morning (am) and evening (pm) domiciliary nasal PIFR and symptom (nasal, eye, throat) scores and impact on daily activity. A total daily symptom score was then calculated from the sum of these separate symptom scores. Results: Baseline values for symptom scores and PIFR after placebo run-in were not significantly different when comparing the three groups. After 4 weeks of active treatment, there were significant ($P < 0.05$) improvements in nasal symptoms, total daily symptoms and PIFR with all treatments, with there being no significant confounding effect of pollen count, when analysed as a covariate. There were significant ($P < 0.01$) correlations for nasal symptom scores vs PIFRam ($r = -0.51$) and PIFRpm ($r = -0.56$), and similarly for daily activity vs PIFRam ($r = -0.42$) and PIFRpm ($r = -0.48$). Conclusions: These results suggest that domiciliary measurements of nasal peak flow correlate significantly with symptoms of seasonal allergic rhinitis and may therefore be a potentially useful objective short-term marker of treatment response.

CT Medical Descriptors:

*allergic rhinitis: DI, diagnosis

*allergic rhinitis: DT, drug therapy

treatment outcome

outcomes research

device

symptomatology

scoring system

diagnostic procedure

human

male

female

clinical article

clinical trial

randomized controlled trial

single blind procedure

controlled study

adult

article

priority journal

Drug Descriptors:

*cetirizine: CT, clinical trial

*cetirizine: CB, drug combination

*cetirizine: CM, drug comparison

*cetirizine: DO, drug dose

*cetirizine: DT, drug therapy

*cetirizine: PO, oral drug administration

*mometasone furoate: CT, clinical trial

*mometasone furoate: CB, drug combination

*mometasone furoate: CM, drug comparison

*mometasone furoate: DO, drug dose

*mometasone furoate: DT, drug therapy

*mometasone furoate: NA, intranasal drug administration

*montelukast: CT, clinical trial

*montelukast: CB, drug combination

*montelukast: CM, drug comparison

*montelukast: DO, drug dose

*montelukast: DT, drug therapy

*montelukast: PO, oral drug administration

placebo

RN (cetirizine) 83881-51-0, 83881-52-1; (mometasone furoate) 83919-23-7; (montelukast) 151767-02-1, 158966-92-8

CN (1) Zirtek; (2) Nasonex; (3) Singulair

NP (1) In-check

CO (1) UCB (United Kingdom); (2) Schering Plough (United Kingdom); (3) Merck Sharp and Dohme (United Kingdom)

CO (1) Clement Clarke (United Kingdom)

L109 ANSWER 4 OF 5 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

AN 2000187564 EMBASE

TI Concomitant **montelukast** and **loratadine** as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial.

AU Meltzer E.O.; Malmstrom K.; Lu S.; Prenner B.M.; Wei L.X.; Weinstein S.E.; Wolfe J.D.; Reiss T.E.

CS Dr. K. Malmstrom, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, United States

SO Journal of Allergy and Clinical Immunology, (2000) 105/5 (917-922). Refs: 23

ISSN: 0091-6749 CODEN: JACIBY

CY United States

DT Journal; Article

FS 030 Pharmacology

037 Drug Literature Index

LA English

SL English

AB Background: Nasal challenge studies have suggested histamine and cysteinyl leukotrienes are important proinflammatory mediators in allergic rhinitis. This study was designed to determine the efficacy of **montelukast**, a cysteinyl leukotriene receptor antagonist, administered alone or concomitantly with **loratadine**, an H1-receptor antagonist, in seasonal allergic rhinitis. Objective: The purpose of this study was to determine the effect of concomitant use of **montelukast** and **loratadine** in the treatment of seasonal allergic rhinitis. Methods: In this multicenter (N = 12) double-blind, randomized, parallel-group, placebo-controlled 2-week trial, 460 men and women, aged 15 to 75 years, with spring seasonal allergic rhinitis were randomly allocated to receive 1 of the following 5 treatments: **montelukast** 10 or 20 mg, **loratadine** 10 mg, **montelukast** 10 mg with **loratadine** 10 mg, or placebo, once daily in the evening. The primary end point was daytime nasal symptoms score (average of congestion, rhinorrhea, itching, and sneezing). Other end points were eye symptoms, nighttime symptoms, individual daytime nasal symptoms, global evaluations (patient's and physician's), and rhinoconjunctivitis quality-of-life scores. Results: Concomitant **montelukast** with **loratadine** improved the primary end point significantly ($P < .001$) compared with placebo and each agent alone. Compared with placebo, **montelukast** with **loratadine** also significantly improved eye symptoms, nighttime symptoms, individual daytime nasal symptoms, global evaluations, and quality of life. **Montelukast** alone and **loratadine** alone caused modest improvements in rhinitis end points. All treatments were similarly well tolerated. Conclusions: Concomitant **montelukast** with **loratadine** provided effective treatment for seasonal allergic rhinitis and associated eye symptoms with a safety

profile comparable with placebo.

CT Medical Descriptors:

- *allergic rhinitis: DT, drug therapy
- drug efficacy
- drug mixture
- scoring system
- nose congestion
- rhinorrhea
- sneezing
- rhinoconjunctivitis
- quality of life
- drug tolerability
- human
- male
- female
- major clinical study
- clinical trial
- randomized controlled trial
- double blind procedure
- multicenter study
- controlled study
- adolescent
- aged
- adult
- article
- priority journal

Drug Descriptors:

- *montelukast: CB, drug combination
- *montelukast: CM, drug comparison
- *montelukast: DO, drug dose
- *montelukast: DT, drug therapy
- *loratadine: CB, drug combination
- *loratadine: DO, drug dose
- *loratadine: DT, drug therapy
- *placebo: CM, drug comparison

RN (montelukast) 151767-02-1, 158966-92-8; (loratadine) 79794-75-5

L109 ANSWER 5 OF 5 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

AN 2000153791 EMBASE

TI **Montelukast**: A review of its therapeutic potential in persistent asthma.

AU Jarvis B.; Markham A.

CS B. Jarvis, Adis International Limited, 41 Centorian Drive, Mairangi Bay, Auckland 10, New Zealand. demail@adis.co.nz

SO Drugs, (2000) 59/4 (891-928).

Refs: 237

ISSN: 0012-6667 CODEN: DRUGAY

CY New Zealand

DT Journal; General Review

FS 015 Chest Diseases, Thoracic Surgery and Tuberculosis

030 Pharmacology

038 Adverse Reactions Titles

036 Health Policy, Economics and Management

037 Drug Literature Index

LA English

SL English

AB **Montelukast** is a cysteinyl leukotriene receptor antagonist used to treat persistent asthma in patients aged .gtoreq.6 years. The drug has a rapid onset of action. Improvements in lung function and reductions in as-needed .beta.2-agonist usage are apparent within 1 day of initiating **montelukast** treatment in adults and adolescents (aged .gtoreq.15 years treated with 10 mg/day) or children (aged 6 to 14 years treated with

5 mg/day) with persistent asthma as shown in clinical trials. In two 12-week, multicentre, randomised, double-blind studies in adults and adolescents aged ≥ 15 years with persistent asthma [forced expiratory volume in 1 second (FEV1) = 50 to 85% predicted] there was significantly ($p < 0.05$) greater improvement in FEV1, symptom scores, peak expiratory flow (PEF), as-needed β_2 -agonist use, peripheral eosinophil counts and health-related quality of life (QOL) in patients treated with **montelukast** 10 mg/day than in recipients of placebo. Improvements were significantly greater in patients treated with inhaled beclomethasone 400 μ g/day than in recipients of **montelukast** 10 mg/day in 1 of these studies. Nonetheless, 42% of **montelukast** recipients experienced $\geq 11\%$ improvement in FEV1, the median improvement in this parameter in beclomethasone-treated patients. In an 8-week multicentre, randomised, double-blind, study in children aged 6 to 14 years with persistent asthma (FEV1 50 to 85% predicted), **montelukast** 5 mg/day produced significantly greater improvements in FEV1, clinic PEF, as-needed β_2 -agonist use, peripheral eosinophil counts, asthma exacerbations and QOL scores than placebo. The combination of **montelukast** 10 mg/day plus inhaled beclomethasone 200 μ g twice daily provided significantly better asthma control than inhaled beclomethasone 200 μ g twice daily in adults with poorly controlled asthma (mean FEV1 = 72% predicted) despite 4 weeks treatment with inhaled beclomethasone. Patients receiving the combination experienced significant improvements in FEV1 and morning PEF, significant reductions in daytime symptom scores, as-needed β_2 agonist usage and night-time awakenings with asthma, and had significantly lower peripheral blood eosinophil counts after 16 weeks in this multicentre, randomised, double-blind, placebo-controlled study. Among adults (FEV1 $\geq 70\%$) treated with **montelukast** 10 mg/day for 12 weeks, inhaled corticosteroid dosages were titrated downward by 47% (vs 30% in placebo recipients), 40% of patients were tapered off of inhaled corticosteroids (vs 29%), and significantly fewer patients (16 vs 30%) experienced failed corticosteroid rescues in a multicentre, randomised, double-blind study. During clinical studies, the frequency of adverse events in **montelukast**-treated adults, adolescents and children was similar to that in placebo recipients. In conclusion, **montelukast** is well tolerated and effective in adults and children aged ≥ 6 years with persistent asthma including those with exercise-induced bronchoconstriction and/or aspirin sensitivity. Furthermore, **montelukast** has glucocorticoid sparing properties. Hence, **montelukast**, as monotherapy in patients with mild persistent asthma, or as an adjunct to inhaled corticosteroids is useful across a broad spectrum of patients with persistent asthma.

CT Medical Descriptors:

*asthma: DT, drug therapy
 *asthma: PC, prevention
 human
 clinical trial
 meta analysis
 nonhuman
 drug receptor binding
 drug effect
 eosinophil
 bronchospasm
 lung function
 drug absorption
 drug distribution
 drug metabolism
 drug excretion
 drug tolerability
 quality of life
 drug inhibition
 bronchodilatation

pharmacodynamics
drug potentiation
headache: SI, side effect
dose response
Churg Strauss syndrome
review

Drug Descriptors:

*montelukast: DT, drug therapy
*montelukast: CM, drug comparison
*montelukast: CT, clinical trial
*montelukast: CB, drug combination
*montelukast: PD, pharmacology
*montelukast: IV, intravenous drug administration
*montelukast: PO, oral drug administration
*montelukast: PK, pharmacokinetics
*montelukast: AE, adverse drug reaction
*montelukast: DO, drug dose
peptidoleukotriene: EC, endogenous compound
beclometasone: DT, drug therapy
beclometasone: IH, inhalational drug administration
beclometasone: CM, drug comparison
beclometasone: CB, drug combination
beclometasone: CT, clinical trial
beclometasone: DO, drug dose
corticosteroid: DT, drug therapy
corticosteroid: IH, inhalational drug administration
corticosteroid: CT, clinical trial
corticosteroid: CB, drug combination
corticosteroid: DO, drug dose
corticosteroid: PO, oral drug administration
nitric oxide: EC, endogenous compound
salbutamol: DT, drug therapy
salbutamol: IH, inhalational drug administration
salmeterol: DT, drug therapy
salmeterol: IH, inhalational drug administration
salmeterol: CM, drug comparison
salmeterol: CB, drug combination
salmeterol: CT, clinical trial
cytochrome P450 isoenzyme: EC, endogenous compound
warfarin: DT, drug therapy
warfarin: CB, drug combination
warfarin: PK, pharmacokinetics
digoxin: DT, drug therapy
digoxin: CB, drug combination
digoxin: PK, pharmacokinetics
terfenadine: DT, drug therapy
terfenadine: CB, drug combination
terfenadine: PK, pharmacokinetics
fexofenadine: DT, drug therapy
fexofenadine: PK, pharmacokinetics
fexofenadine: CB, drug combination
ethinylestradiol plus norethisterone: DT, drug therapy
ethinylestradiol plus norethisterone: CB, drug combination
ethinylestradiol plus norethisterone: PK, pharmacokinetics
theophylline: DT, drug therapy
theophylline: PK, pharmacokinetics
theophylline: CT, clinical trial
theophylline: IV, intravenous drug administration
theophylline: CB, drug combination
theophylline: PO, oral drug administration
prednisone: DT, drug therapy
prednisone: CB, drug combination
prednisone: PO, oral drug administration

prednisone: PK, pharmacokinetics
 prednisolone: DT, drug therapy
 prednisolone: CB, drug combination
 prednisolone: PK, pharmacokinetics
 prednisolone: IV, intravenous drug administration
 phenobarbital: DT, drug therapy
 phenobarbital: CB, drug combination
 phenobarbital: IT, drug interaction
 loratadine: DT, drug therapy
 loratadine: CT, clinical trial
 loratadine: CB, drug combination
 loratadine: PO, oral drug administration
 cromoglycate disodium: DT, drug therapy
 cromoglycate disodium: CT, clinical trial
 cromoglycate disodium: CM, drug comparison
 cromoglycate disodium: IH, inhalational drug administration
 nedocromil: DT, drug therapy
 nedocromil: IH, inhalational drug administration
 leukotriene receptor blocking agent: DT, drug therapy
 leukotriene receptor blocking agent: PO, oral drug administration
 pranlukast: DT, drug therapy
 pranlukast: PK, pharmacokinetics
 pranlukast: CM, drug comparison
 zileuton: DT, drug therapy
 zileuton: PO, oral drug administration
 RN (montelukast) 151767-02-1, 158966-92-8;
 (beclometasone) 4419-39-0; (nitric oxide) 10102-43-9; (salbutamol)
 18559-94-9; (salmeterol) 89365-50-4; (warfarin) 129-06-6, 2610-86-8,
 3324-63-8, 5543-58-8, 81-81-2; (digoxin) 20830-75-5, 57285-89-9;
 (terfenadine) 50679-08-8; (fexofenadine) 138452-21-8;
 (ethinylestradiol plus norethisterone) 37270-71-6; (theophylline) 58-55-9,
 5967-84-0, 8055-07-0, 8061-56-1, 99007-19-9; (prednisone) 53-03-2;
 (prednisolone) 50-24-8; (phenobarbital) 50-06-6, 57-30-7, 8028-68-0; (
 loratadine) 79794-75-5; (cromoglycate disodium) 15826-37-6,
 16110-51-3, 93356-79-7, 93356-84-4; (nedocromil) 69049-73-6; (pranlukast)
 103177-37-3; (zileuton) 111406-87-2, 132880-11-6

=> fil wpix

FILE 'WPIX' ENTERED AT 14:33:28 ON 09 MAR 2003

COPYRIGHT (C) 2003 THOMSON DERWENT

FILE LAST UPDATED: 7 MAR 2003 <20030307/UP>
 MOST RECENT DERWENT UPDATE: 200316 <200316/DW>
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> DUE TO TECHNICAL ISSUES THE SDIS FOR UPDATES 200302-200304
 BASED ON ENTRY DATE (ED) MAY CONTAIN DOCUMENTS PREVIOUSLY
 DISTRIBUTED. IF YOU ENCOUNTER ANY SURPLUS DOCUMENTS OF THIS
 KIND, PLEASE CONTACT OUR HELPDESKS. UNJUSTIFIED CHARGES
 INCURRED WILL BE REVOKED OF COURSE.
 WE APOLOGIZE FOR ANY INCONVENIENCE CAUSED. <<<

>>> SLART (Simultaneous Left and Right Truncation) is now
 available in the /ABEX field. An additional search field
 /BIX is also provided which comprises both /BI and /ABEX <<<

>>> PATENT IMAGES AVAILABLE FOR PRINT AND DISPLAY <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES,
 SEE <http://www.derwent.com/dwpi/updates/dwpicov/index.html> <<<

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
GUIDES, PLEASE VISIT:
http://www.derwent.com/userguides/dwpi_guide.html <<<

=> d all abeq tech abex tot

L119 ANSWER 1 OF 9 WPIX (C) 2003 THOMSON DERWENT

AN 2002-740979 [80] WPIX

DNC C2002-209930

TI Composition for treatment of asthma, particularly bronchial asthma,
comprising a pair of compatible receptor antagonists and a leukotriene
receptor antagonist.

DC B05

IN KAURA, S R

PA (KAUR-I) KAURA S R

CYC 100

PI WO 2002080916 A1 20021017 (200280)* EN 21p A61K031-44

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
NL OA PT SD SE SL SZ TR TZ UG ZM ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT
RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM
ZW

US 2002198228 A1 20021226 (200304) A61K031-473

ADT WO 2002080916 A1 WO 2002-US10306 20020403; US 2002198228 A1 US 2001-825258
20010403

PRAI US 2001-825258 20010403

IC ICM A61K031-44; A61K031-473

ICS A61K031-135; A61K031-47

AB WO 200280916 A UPAB: 20021212

NOVELTY - Composition for the treatment of asthma comprises a first
receptor antagonist and a second receptor antagonist, both being selected
from leukotriene receptor antagonists and histamine receptor antagonists,
and an adrenergic bronchodilator.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) a composition for the treatment of asthma comprising:

(a) a first receptor antagonist with a first chemical composition;

(b) a second receptor antagonist with a second chemical composition,

where (a) and (b) are chemically dissimilar; and

(c) an adrenergic bronchodilator;

(2) a composition for the treatment of asthma comprising

montelukast sodium, an antihistamine selected from

cetirizine, **loratadine** and **fexofenadine**, and a

sympathomimetic bronchodilator; and

(3) a method for treating asthma comprising:

(a) preparing a composition comprising a first receptor antagonist
(4.0-20.0 mg), a second receptor antagonist (2.5-180.0 mg), the second
receptor antagonist being different from the first; an adrenergic
bronchodilator (4.0-8.0 mg); and

(b) administering the composition to a patient.

ACTIVITY - Antiinflammatory; Antiasthmatic; Respiratory.

25 Asthmatic patients were administered a composition of the
invention. The asthma endpoints were studies both as primary and secondary
endpoints. According to the primary endpoints, at forced expiratory volume
1 (FEV1) which were daytime endpoints, the patients showed marked
improvement in both FEV1 and daytime asthma symptoms. According to the
secondary endpoints, or nighttime peak expiratory flow rate, the patients

demonstrated marked improvement in this category and did not suffer as much with nocturnal awakenings due to asthmatic episodes compared with previous nights without treatment using the composition. The use of beta-agonist inhalers was significantly reduced in both the number of inhalations used daily and the percentage of days when the inhaler was actually used.

MECHANISM OF ACTION - Leukotriene Receptor Antagonist; Histamine Receptor Antagonist; Adrenergic Bronchodilator.

USE - The invention is for the treatment of respiratory disease, particularly bronchial asthma and related conditions (e.g. chronic obstructive pulmonary disease (COPD) or bronchitis), as well as any condition in which temporary inflammation of the bronchioles caused by bacterial and viral infections including inflammation of the bronchial tubes associated with both acute and chronic infection.

ADVANTAGE - The invention mitigates the adverse effects of asthma, particularly bronchial asthma. It provides flexibility of dosage schedule.
Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B06-D01; B06-D02; B06-D13; B07-D05; B07-D11; B14-K01A; B14-L08;
B14-L09

TECH UPTX: 20021212

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Materials: The adrenergic bronchodilator is a beta2-adrenergic bronchodilator, preferably albuterol sulfate. The leukotriene antagonist is selected from **montelukast** sodium and zafirlukast sodium. The histamine receptor (sic) is a histamine H1-receptor antagonist selected from ceterizine hydrochloride, **loratadine** and **fexofenadine**..

ABEX

ADMINISTRATION - Administration is oral. No dosage given.

L119 ANSWER 2 OF 9 WPIX (C) 2003 THOMSON DERWENT

AN 2002-500604 [53] WPIX

DNC C2002-141828

TI Pharmaceutical aerosol formulation comprising an alkylpolyglycoside surfactant.

DC B05 B07

IN BUCKTON, G; COLUMBANO, A; GROSVENOR, M; WIKLEY, P

PA (ASTR) ASTRAZENCA AB

CYC 100

PI WO 2002049616 A1 20020627 (200253)* EN 33p A61K009-12

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
NL OA PT SD SE SL SZ TR TZ UG ZM ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT
RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM
ZW

AU 2002016576 A 20020701 (200264) A61K009-12

ADT WO 2002049616 A1 WO 2001-SE2853 20011219; AU 2002016576 A AU 2002-16576
20011219

FDT AU 2002016576 A Based on WO 200249616

PRAI SE 2000-4750 20001219

IC ICM A61K009-12

ICS A61K047-26

AB WO 200249616 A UPAB: 20021031

NOVELTY - A pharmaceutical aerosol formulation comprises a hydrofluoroalkane propellant, a medicament for inhalation and an alkylpolyglycoside surfactant (I).

DETAILED DESCRIPTION - A pharmaceutical aerosol formulation comprises a hydrofluoroalkane propellant, a medicament for inhalation and an alkylpolyglycoside surfactant of formula (I) or its derivative.

DP = average degree of polymerisation from 1-4; and

R = 6-22C alkyl.

ACTIVITY - Respiratory.

No details of tests showing activity are given in the specification.

MECHANISM OF ACTION - None given.

USE - Administration of medicaments for inhalation, for treating respiratory and nasal disorders.

ADVANTAGE - The surfactants are highly surface active, have low ecotoxicity and improve the stability of the formulation. They can be synthesized with a range of properties such as molecular weight and degree of polymerisation.

DESCRIPTION OF DRAWING(S) - The figure shows an optical suspension characterization of beclomethasone dipropionate (BDP) + C12G2 in HFA-134a. Dwg.1/12

FS CPI

FA AB; GI; DCN

MC CPI: B01-B02; B01-B03; B01-D01; B06-D01; B06-D02; B06-D13; B06-F01; B10-B02F; B10-B03B; B10-H02B; B12-M01A; B12-M01B; B14-K01; B14-N04

TECH UPTX: 20020820

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Medicament: The medicament is a beta2-adrenoreceptor agonist, an anticholinergic bronchodilator, or a 16,17-acetal of a pregnane derivative, especially formoterol, terbutaline, budesonide, or a formoterol/budesonide combination. Also preferred are compounds of formula Ar-CH2-CH2-NH-CR1R2-A-Z (II) and derivatives.

Ar = group of formula (i);

A = 1-12C straight or branched alkylene interrupted or terminated by one or more of S, SO, SO2, O, SO2NH, NHSO2, CR6R7, phenylmethyne, NH, CONH, NHCO, and NHCONH;

Z = 5-6 atom aryl in a single ring, optionally containing 1-3 of N, O and S, and optionally substituted to form a multiple fused ring system of up to 10 atoms, and the aryl optionally substituted by one or more of OH, halogen, 1-6C alkyl, 1-6C alkoxy, =O, NR8R9 or NO2; or Z = 3-12C cycloalkyl optionally containing 1-3 of N, O and S, optionally substituted by OH, halogen, 1-6C alkyl, 1-6C alkoxy, =O, NH2, or NO2;

R1, R2, R5-R9 = H or 1-6C alkyl;

R3, R4 = H; or

R3 + R4 = -S-, -NR8- or -CH2-.

Preferred Formulation: The formulation contains 0.001 wt.% surfactant, and 0.01-1.0 wt.% medicament.

ABEX

SPECIFIC COMPOUNDS - The use of 2 compounds as the alkylpolyglycoside is specifically claimed, e.g. n-dodecyl beta-D-maltoside (C12G2), C10d.p.2.7, or C10-12d.p.1.4 and C12-14 d.p.

The use of 5 compounds as the medicament is specifically claimed, e.g. 4-hydroxy-7-(2-(2-(3-(2-phenylethoxy)propylsulfonyl)ethylamino)ethyl)-1,3-benzothiazol-2(3H)-one, 4-hydroxy-7-(2-(2-(3-(2-phenylethoxy)propoxy)ethylamino)ethyl)-1,3-benzothiazol-2(3H)-one, N-(2-(2-(4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl)ethylamino)ethyl)-2-(phenylethoxy)ethanesulfonamide, 4-hydroxy-7-(2-(3-(2-(2-(1-naphthalenyl)ethoxy)ethylsulfonyl)propylamino)ethyl)-1,3-benzothiazol-2(3H)-one and 3-(2-(4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl)ethylamino)-N-(2-(2-(4-methylphenyl)ethoxy)ethyl)propanesulfonamide.

Preferred specifically claimed combinations of the medicaments include e.g. formoterol/budesonide, formoterol/fluticasone, formoterol/mometasone, salmeterol/fluticasone, formoterol/tiotropium salts, zafirlukast/formoterol, zafirlukast/budesonide, montelukast/formoterol, montelukast/budesonide, loratadine/montelukast and loratadine/zafirlukast, tiotropium and fluticasone, tiotropium and budesonide, tiotropium and mometasone, mometasone and salmeterol, formoterol and rofleponide, salmeterol and budesonide, salmeterol and rofleponide or tiotropium and rofleponide. The use of 2 compounds as the propellant is specifically claimed, i.e. HFA-134a and/or HFA-227ea.

EXAMPLE - A formulation was prepared by placing beclomethasone dipropionate (BDP) (0.2 g) into a phial and adding surfactant solution (20 ml) comprising C12G2 (0.8 g/l). the suspension was incubated in a shaking bath at 25 degrees C for 3 hours. to allow adsorption of the surfactant onto the drug surface, and giving a drug-surfactant ratio of 10 mg surfactant/g drug. The suspension was centrifuged (15,000 rpm for 20 minutes) and the particles of drug-surfactant were separated from the supernatant and dried at 50 degrees C for 24 hours. The resulting formulation had concentrations of BDP + C12G2 of 0.2%, and HFA-134a to 100%. The stability of the suspension increased from 10 seconds for a control without surfactant to over one minute with it.

DEFINITIONS - Preferred Definitions:

R = 2-ethyl-1-hexylglycoside and DP = 1.6;

R = mixture of 8C and 10C alkyl chains in a ratio of 60C8:40C10, and DP = 1.5;

R = mixture of 16C and 8C chains, and DP = 1.2-1.3; or

R = mixture of 20C and 22C chains, and DP = 1.2-1.3.

L119 ANSWER 3 OF 9 WPIX (C) 2003 THOMSON DERWENT

AN 2002-479010 [51] WPIX

DNC C2002-136224

TI Treating and/or preventing cardiovascular disease e.g. atherosclerosis comprises loratadine and montelukast.

DC B02

IN HARRIS, A G; MEDEIROS, P T

PA (SCHE) SCHERING CORP

CYC 95

PI US 2002052388 A1 20020502 (200251)* 5p A61K031-473

WO 2002036124 A2 20020510 (200251) EN A61K031-47

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ

NL OA PT SD SE SL SZ TR TZ UG ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM

DZ EC EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT

LU LV MA MD MG MK MN MX MZ NO NZ PH PL PT RO RU SE SG SI SK SL TJ

TM TR TT TZ UA US UZ VN YU ZA

AU 2002027240 A 20020515 (200258) A61K031-47

ADT US 2002052388 A1 Provisional US 2000-244226P 20001030, US 2001-12920 20011030; WO 2002036124 A2 WO 2001-US46596 20011026; AU 2002027240 A AU 2002-27240 20011026

FDT AU 2002027240 A Based on WO 200236124

PRAI US 2000-244226P 20001030; US 2001-12920 20011030

IC ICM A61K031-47; A61K031-473

ICS A61P009-00

AB US2002052388 A UPAB: 20020812

NOVELTY - Treating and/or preventing a cardiovascular disease comprises administering loratadine or its salts in combination with montelukast or its salts.

ACTIVITY - Cardiant; Antiarteriosclerotic; Antianginal; Cerebroprotective; Vasotropic.

MECHANISM OF ACTION - H1-histamine receptor antagonist; Leukotriene D4 antagonist.

No biological data is given.

USE - Used for treating and/or preventing cardiovascular disease, particularly atherosclerosis, ischemic heart disease or cerebrovascular disease such as coronary artery disease including angina pectoris, myocardial infarction, stroke, vascular heart disease and peripheral vascular disorders such as peripheral arterial disease and occlusive arterial disease, in patients suffering from an allergic and/or inflammatory condition e.g. seasonal allergic rhinitis, perennial allergic rhinitis, atopic dermatitis, urticaria, allergic asthma, non-allergic rhinitis, non-allergic asthma, sinusitis, colds, allergic dermatitis, chronic obstructive lung disease, and type 2 diabetes.

ADVANTAGE - The safe and effective therapy reduces serum immunoglobulin and/or eosinophil levels in patients at risk of cardiovascular disease.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B06-D02; B06-D13; B14-A02; B14-A02B3; B14-C03; B14-F01B; B14-F01D; B14-F01E; B14-F02; B14-F02D1; B14-F07; B14-G02A; B14-K01; B14-L08; B14-L10; B14-N04; B14-N16; B14-N17C; B14-S04

ABEX

ADMINISTRATION - **Loratadine** is administered in a dosage of 1-45 (particularly 10) mg/day. **Montelukast** is administered in a dosage of 5-20 (preferably 10) mg/day. Administration is oral, parenteral (including subcutaneous, intramuscular, intravenous or intraperitoneal), topical, vaginal or by inhalation (orally or intranasally) 1 or 2 times per day, preferably once a day.

EXAMPLE - None given in the source material.

L119 ANSWER 4 OF 9 WPIX (C) 2003 THOMSON DERWENT

AN 2001-523343 [58] WPIX

DNC C2001-156413

TI Composition for treating allergic and/or vasomotor rhinitis or allergic conjunctivitis by topical or oral administration, contains synergistic combination of non-sedating antihistamine and leukotriene antagonist.

DC B05

IN ENGEL, J; POPPE, H; SZELENYI, I; KUSS, H

PA (ASTA) ASTA MEDICA AG; (VIAT-N) VIATRIS GMBH & CO KG; (ENGE-I) ENGEL J; (POPP-I) POPPE H; (SZEL-I) SZELENYI I

CYC 57

PI DE 10007203 A1 20010823 (200158)* 9p A61K031-55

WO 2001060407 A2 20010823 (200158) DE A61K045-00

RW: AT BE CH CY DE DK EA ES FI FR GB GR IE IT LU MC NL PT SE TR

W: AU BG BR BY CN CZ EE GE HR HU ID IL IN IS JP KG KR KZ LT LV MK MX

NO NZ PL RO RU SG SI SK TR UA UZ YU ZA

US 2001025040 A1 20010927 (200159) A61K031-55

AU 2001040584 A 20010827 (200176) A61K045-00

US 6436924 B1 20020820 (200257) A61K031-55

NO 2002003818 A 20020812 (200277) A61K000-00

SK 2002001175 A3 20021106 (200281) A61K045-00

CZ 2002002700 A3 20021113 (200282) A61K045-00

EP 1265615 A2 20021218 (200301) DE A61K031-55

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR

ADT DE 10007203 A1 DE 2000-10007203 20000217; WO 2001060407 A2 WO 2001-EP1190 20010205; US 2001025040 A1 US 2001-784640 20010215; AU 2001040584 A AU 2001-40584 20010205; US 6436924 B1 US 2001-784640 20010215; NO 2002003818 A WO 2001-EP1190 20010205, NO 2002-3818 20020812; SK 2002001175 A3 WO 2001-EP1190 20010205, SK 2002-1175 20010205; CZ 2002002700 A3 WO 2001-EP1190 20010205, CZ 2002-2700 20010205; EP 1265615 A2 EP 2001-911591 20010205, WO 2001-EP1190 20010205

FDT AU 2001040584 A Based on WO 200160407; SK 2002001175 A3 Based on WO 200160407; CZ 2002002700 A3 Based on WO 200160407; EP 1265615 A2 Based on WO 200160407

PRAI DE 2000-10007203 20000217

IC ICM A61K000-00; A61K031-55; A61K045-00

ICS A61K031-47; A61P037-08

AB DE 10007203 A UPAB: 20011010

NOVELTY - Pharmaceutical composition comprises (separately or in combination):

(A) a non-sedating antihistamine (or its salt), other than compounds of the **loratadine** type;

(B) a leukotriene antagonist (or its salt) comprising (B1)

leukotriene D4 antagonists, (B2) 5-lipoxygenase inhibitors or (B3) FLAP (5-lipoxygenase activating protein) antagonists; and
(C) conventional carriers and/or extenders or auxiliaries.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

- (i) the use of a combination of (A)-(C) for the preparation of a medicament for use as above;
- (ii) a medicament comprising (A)-(C), for use as above; and
- (iii) the preparation of the medicaments, by mixing and formulating the appropriate components.

ACTIVITY - Antiallergic; antiinflammatory; ophthalmological.

In tests for inhibition of ovalbumin-induced nasal mucosal permeability in sensitized rats, the degree of inhibition was 11% using azelastine alone at 0.01 mg/kg i.p., 7% using **montelukast** alone at 0.1 mg/kg i.p. and 40% using a combination of azelastine at 0.01 mg/kg i.p. and **montelukast** at 0.1 mg/kg i.p.

MECHANISM OF ACTION - Antihistamine; leukotriene D4 antagonist; 5-lipoxygenase inhibitor; FLAP (5-lipoxygenase activating protein) antagonist.

USE - Used for treating allergic and/or vasomotor rhinitis or allergic conjunctivitis.

ADVANTAGE - The combination of (A) and (B) is synergistic, highly effective, safe and free of side-effects. (A) rapidly alleviates acute symptoms of rhinitis or conjunctivitis (e.g. redness, itching and swelling) and (B) effectively combats the inflammation which is the underlying cause of the disease.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B06-H; B07-D05; B07-D11; B14-C03; B14-G02A; B14-N03; B14-N04;

B14-S09

ABEX

SPECIFIC COMPOUNDS - (A) is azelastine (most preferred), levocabastine, **cetirizine**, **fexofenadine**, mizolastine or **astemizole**; (B1) is **montelukast**, zefirlukast or pranlukast; (B2) is zileuton, piriprost or AWD 23-115; and (B3) is MK-591, MK-886 or Bay x 1005 (all claimed).

ADMINISTRATION - The compositions contain 0.001-5% (A) and 0.01-5% of (B1), (B2) or (B3); and are formulated for topical administration (especially as a spray, nose drops or eye drops) or oral administration (all claimed). For topical administration, unit doses are 50-500 (preferably 200-400) mug of (A) and 100-2000 (preferably 200-1000) mug of (B1) or 50-2000 (preferably 200-1000) mug of (B2) or (B3), applied once or twice daily. For oral administration, daily doses are 0.5-16 (preferably 2-8) mg of (A) and 1-50 (preferably 5-10) mg of (B1), 1-6 (preferably 0.6-2) g of (B2) or 50-2000 (preferably 100-50) mg of (B3)

EXAMPLE - Nose drops comprised 0.1 g azelastine hydrochloride, 0.1 g hydroxypropyl methyl cellulose, 0.05 g sodium edetate, 0.0125 g benzalkonium chloride, sodium hydroxide to give pH 6.0, 6.6666 g 70% sorbitol solution and purified water to a total of 100 ml.

L119 ANSWER 5 OF 9 WPIX (C) 2003 THOMSON DERWENT

AN 1999-633803 [54] WPIX

DNC C1999-185089

TI Treating asthma using **cetirizine** and leukotriene inhibitor.

DC B02 B03

IN RUBIN, P D

PA (SEPR-N) SEPRACOR INC

CYC 87

PI WO 9952553 A1 19991021 (199954)* EN 34p A61K045-06

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL

OA PT SD SE SL SZ UG ZW

W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB
 GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU
 LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR
 TT UA UG UZ VN YU ZA ZW

AU 9935580 A 19991101 (200013)

EP 1071461 A1 20010131 (200108) EN A61K045-06

R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

US 6384038 B1 20020507 (200235) A61K031-495

JP 2002511425 W 20020416 (200242) 32p A61K031-495

US 2002099058 A1 20020725 (200254) A61K031-495

ADT WO 9952553 A1 WO 1999-US8076 19990413; AU 9935580 A AU 1999-35580
 19990413; EP 1071461 A1 EP 1999-917463 19990413, WO 1999-US8076 19990413;
 US 6384038 B1 US 1998-59571 19980414; JP 2002511425 W WO 1999-US8076
 19990413, JP 2000-543163 19990413; US 2002099058 A1 Div ex US 1998-59571
 19980414, US 2002-105331 20020326

FDT AU 9935580 A Based on WO 9952553; EP 1071461 A1 Based on WO 9952553; JP
 2002511425 W Based on WO 9952553; US 2002099058 A1 Div ex US 6384038

PRAI US 1998-59571 19980414; US 2002-105331 20020326

IC ICM A61K031-495; A61K045-06

ICS A61K031-381; A61K031-404; A61K031-41; A61K031-4365; A61K031-47;
 A61K045-00; A61P011-06

ICI A61K031-495; A61K031-495; A61K031-495; A61K031-495; A61K031-495;
 A61K031:381; A61K031:404; A61K031:41; A61K031:4365; A61K031:47

AB WO 9952553 A UPAB: 19991221

NOVELTY - Treatment or prevention of asthma or its symptoms, dermatitis,
 allergic rhinitis, inflammation or a condition responsive to leukotriene
 inhibition, comprises administering **cetirizine** or its salts and
 a leukotriene inhibitor or its salts.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a
 composition comprising **cetirizine**, leukotriene inhibitor and
 carrier or excipient.

ACTIVITY - Antihistaminic; antiasthmatic; antiallergic;
 antiinflammatory; dermatological; ocular.

MECHANISM OF ACTION - H1 histamine receptor antagonist; leukotriene
 inhibitor.

USE - Useful for treating or preventing or managing asthma, asthma
 symptoms, inflammation, allergic rhinitis, other allergic disorders and
 dermatitis. The composition is also useful in combination with
 non-steroidal antiinflammatory agents or other non-narcotic analgesics for
 the treatment of cough, cold, cold-like and/or flu symptoms and the
 associated discomfort, headache, pain, fever and general malaise.

The composition is also useful for treating, preventing or managing,
 motion sickness, vertigo, diabetic retinopathy, small vessel complications
 due to diabetes and similar conditions.

ADVANTAGE - The composition reduces or prevents the adverse effects
 associated with the administration of other non-sedating antihistamines
 such as racemic **cetirizine** or an enantiomer of
cetirizine. The **cetirizine** and leukotriene inhibitor
 have a synergistic effect.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B07-D11; B14-C03; B14-D05C; B14-G02A; B14-K01A; B14-L08; B14-N04;
 B14-N17C

TECH UPTX: 19991221

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The
 leukotriene inhibitor comprises 5-lipoxygenase inhibitors, 5-lipoxygenase
 activating protein antagonists and/or leukotriene receptor antagonists.
 The composition also comprises a decongestant.

The 5-lipoxygenase inhibitor comprises zileuton, docebenone, piripost
 and/or ICI-D2318. The 5-lipoxygenase activating protein comprises MK-591
 and/or MK-886. The leukotriene receptor antagonist comprises zafirlukast,
montelukast, pranlukast, sodium 1-((R)-(3-(2-(6,7-difluoro-2-

quinolinyl)ethynyl)phenyl)-3-(2-(2-hydroxy-2-propyl)phenyl)thio)methyl)cyclopropaneacetate, 1-(((1(R)-(3-(2-(2,3-dichlorothieno(3,2-b)pyridin-5-yl)-(E)-ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid and/or their salts.

ABEX

ADMINISTRATION - Administration is concurrently or sequentially. Administration is e.g. oral, intraoral, rectal, parenteral, epicutaneous, transdermal, subcutaneous, intramuscular, intranasal, sublingual, buccal, intradural, intraocular, intrarespiratory or by nasal inhalation. The dosage of cetirizine is 0.01-50 (preferably 1-30) mg/day, in a single or divided doses. Decongestant, e.g. pseudoephedrine, is administered at 50-300 (preferably 150-250) mg/day. The dosage of 5-lipoxygenase inhibitors is 20-2500 (preferably 20-800) mg/day. The oral dosage of leukotriene receptor antagonists is 2-100 (preferably 5-20) mg/day.

L119 ANSWER 6 OF 9 WPIX (C) 2003 THOMSON DERWENT

AN 1999-620293 [53] WPIX

DNC C1999-181054

TI Treatment or prevention of asthma or its symptoms, dermatitis, allergic rhinitis, inflammation or a condition responsive to leukotriene inhibition.

DC B02

IN RUBIN, P D

PA (SEPR-N) SEPRACOR INC

CYC 87

PI WO 9952555 A1 19991021 (199953)* EN 30p A61K045-06

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
OA PT SD SE SL SZ UG ZW

W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB
GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU
LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR
TT UA UG UZ VN YU ZA ZW

AU 9935581 A 19991101 (200013)

EP 1071462 A1 20010131 (200108) EN A61K045-06

R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

US 6248308 B1 20010619 (200137) A61K009-12

US 6372197 B1 20020416 (200232) A61K009-12

JP 2002511427 W 20020416 (200242) 26p A61K031-454

US 2002086854 A1 20020704 (200247) A61K031-454

ADT WO 9952555 A1 WO 1999-US8078 19990413; AU 9935581 A AU 1999-35581

19990413; EP 1071462 A1 EP 1999-917464 19990413; WO 1999-US8078 19990413;

US 6248308 B1 US 1998-59572 19980414; US 6372197 B1 Cont of US 1998-59572

19980414, US 2000-721668 20001127; JP 2002511427 W WO 1999-US8078

19990413, JP 2000-543165 19990413; US 2002086854 A1 Cont of US 1998-59572

19980414, Div ex US 2000-721668 20001127, US 2002-84250 20020228

FDT AU 9935581 A Based on WO 9952555; EP 1071462 A1 Based on WO 9952555; US

6372197 B1 Cont of US 6248308; JP 2002511427 W Based on WO 9952555; US

2002086854 A1 Cont of US 6248308, Div ex US 6372197

PRAI US 1998-59572 19980414; US 2000-721668 20001127; US 2002-84250 20020228

IC ICM A61K009-12; A61K031-454; A61K045-06

ICS A61K009-00; A61K031-415; A61P011-06; A61P017-00; A61P027-16;
A61P029-00; A61P037-08

AB WO 9952555 A UPAB: 19991215

NOVELTY - Treatment or prevention of asthma or its symptoms, dermatitis, allergic rhinitis, inflammation or a condition responsive to leukotriene inhibition, comprises administering **norastemizole** or its salt and a leukotriene inhibitor or its salt.

DETAILED DESCRIPTION - Treatment or prevention of asthma or its symptoms, dermatitis, allergic rhinitis, inflammation or a condition responsive to leukotriene inhibition comprises administering **norastemizole** or its salt and a leukotriene inhibitor or its salt

where the leukotriene inhibitor is selected from 5-lipoxygenase inhibitors, 5-lipoxygenase activating protein antagonists and/or leukotriene receptor antagonists. The composition may further comprise a decongestant.

ACTIVITY - Anti-histaminic; anti-asthmatic; anti-allergic; dermatological; anti-inflammatory.

USE - The compositions have potent anti-histaminic activity and are useful for treating, preventing or managing asthma, asthma symptoms, inflammation, allergic rhinitis and other allergic disorders, as well as dermatitis. The compositions may also be useful for treating, preventing or managing motion sickness, vertigo, diabetic retinopathy, small vessel complications due to diabetes and similar conditions. The compositions are also useful in combination with non-steroidal anti-inflammatory agents or other non-narcotic analgesics for the treatment of cough, cold, cold-like and/or flu symptoms and the discomfort, headache, pain, fever and general malaise associated with these.

ADVANTAGE - The composition may be used to treat, prevent or manage the disorders described while reducing or avoiding the adverse effects associated with the administration of other non-sedating antihistamines such as **atezimole**. The **norastemizole** and the leukotriene inhibitor have a synergistic effect.

Dwg.0/0

FS

CPI

FA

AB; DCN

MC

CPI: B06-A01; B06-B01; B06-D01; B06-D02; B06-D05; B06-F03; B10-A06; B10-B03B; B14-C01; B14-C03; B14-C04; B14-D05C; B14-K01A; B14-K01B; B14-L08; B14-L09; B14-N03; B14-N04; B14-N17C; **B14-S09**

ABEX

SPECIFIC COMPOUNDS - The 5-lipoxygenase inhibitor is selected from zileuton, docebenone, piripost and/or ICI-D2318. The 5-lipoxygenase activating protein is selected from MK-591 and/or MK-886. The leukotriene receptor antagonist is selected from zafirlukast, **montelukast**, pranlukast, sodium 1-(((R)-(3-(2-(6,7-difluoro-2-quinolinyl)ethynyl)phenyl)-3-(2-(2-hydroxy-2-propyl)phenyl)thio)methyl)cyclopropaneacetate and/or 1-(((1R)-(3-(2-(2,3-dichlorothieno(3,2-b)pyridin-5-yl)-(E)-ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid and their salts.

ADMINISTRATION - Administration may be concurrently or sequentially. Administration may be by any suitable route e.g. oral, intraoral, rectal, parenteral, epicutaneous, transdermal, subcutaneous, intramuscular, intranasal, sublingual, buccal, intradural, intraocular, intrarespiratory or by nasal inhalation. Oral administration is generally preferred, but in the treatment of dermatitis, topical administration is preferred. Dosage of **norastemizole** is 1-200 (preferably 10-100) mg/day, in a single or divided doses. Decongestant, e.g. pseudoephedrine, is administered at 50-300 (preferably 150-250) mg/day. Dosage for leukotriene inhibitors depends on the compound employed e.g. for 5-lipoxygenase inhibitors, the daily dosage is 20-2500 (preferably 20-800) mg; for leukotriene receptor antagonists, daily oral dosage is 2-100 (preferably 5-20) mg.

EXAMPLE - No examples given.

L119 ANSWER 7 OF 9 WPIX (C) 2003 THOMSON DERWENT

AN 1999-611163 [52] WPIX

DNC C1999-178006

TI Treatment or prevention of asthma or its symptoms, dermatitis, allergic rhinitis, inflammation or a condition responsive to leukotriene inhibition.

DC B05

IN RUBIN, P D

PA (SEPR-N) SEPRACOR INC; (RUBI-I) RUBIN P D

CYC 87

PI WO 9952554 A1 19991021 (199952)* EN 33p A61K045-06
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
 OA PT SD SE SL SZ UG ZW
 W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB
 GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU
 LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR
 TT UA UG UZ VN YU ZA ZW
 AU 9936409 A 19991101 (200013)
 BR 9909641 A 20001219 (200103) A61K045-06
 NO 2000005147 A 20001107 (200103) A61K000-00
 EP 1071463 A1 20010131 (200108) EN A61K045-06
 R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
 US 6194431 B1 20010227 (200114) A01N043-42
 ZA 2000005553 A 20010725 (200147) 43p A61K000-00
 CN 1305385 A 20010725 (200164) A61K045-06
 KR 2001042655 A 20010525 (200168) A61K045-06
 MX 2000009972 A1 20010401 (200171) A61K045-06
 HU 2001002239 A2 20020328 (200234) A61K031-445
 JP 2002511426 W 20020416 (200242) 30p A61K031-445
 US 6509353 B1 20030121 (200309) A61K031-445
 ADT WO 9952554 A1 WO 1999-US8077 19990413; AU 9936409 A AU 1999-36409
 19990413; BR 9909641 A BR 1999-9641 19990413; WO 1999-US8077 19990413; NO
 2000005147 A WO 1999-US8077 19990413; NO 2000-5147 20001013; EP 1071463 A1
 EP 1999-918515 19990413; WO 1999-US8077 19990413; US 6194431 B1 US
 1998-59570 19980414; ZA 2000005553 A ZA 2000-5553 20001010; CN 1305385 A
 CN 1999-807374 19990413; KR 2001042655 A KR 2000-711354 20001013; MX
 2000009972 A1 MX 2000-9972 20001012; HU 2001002239 A2 WO 1999-US8077
 19990413; HU 2001-2239 19990413; JP 2002511426 W WO 1999-US8077 19990413;
 JP 2000-543164 19990413; US 6509353 B1 Div ex US 1998-59570 19980414, US
 2000-722395 20001128
 FDT AU 9936409 A Based on WO 9952554; BR 9909641 A Based on WO 9952554; EP
 1071463 A1 Based on WO 9952554; HU 2001002239 A2 Based on WO 9952554; JP
 2002511426 W Based on WO 9952554; US 6509353 B1 Div ex US 6194431
 PRAI US 1998-59570 19980414; US 2000-722395 20001128
 IC ICM A01N043-42; A61K000-00; A61K031-445; A61K045-06
 ICS A01N043-40; A61K031-17; A61K031-35; A61K031-38; A61K031-381;
 A61K031-404; A61K031-41; A61K031-4365; A61K031-47; A61K045-00;
 A61P011-00; A61P011-06; A61P017-00; A61P027-16; A61P029-00;
 A61P037-08
 ICI A61K031-445; A61K031-445; A61K031-445; A61K031-445; A61K031:381;
 A61K031:404; A61K031:4365; A61K031:47
 AB WO 9952554 A UPAB: 19991210
 NOVELTY - Treatment or prevention of asthma or its symptoms, dermatitis,
 allergic rhinitis, inflammation or a condition responsive to leukotriene
 inhibition, comprises administering a terfenadine metabolite and a
 leukotriene inhibitor or their salts.
 DETAILED DESCRIPTION - Treatment or prevention of asthma or its
 symptoms, dermatitis, allergic rhinitis, inflammation or a condition
 responsive to leukotriene inhibition comprises administering a terfenadine
 metabolite and a leukotriene inhibitor or their salts where the
 leukotriene inhibitor is selected from 5-lipoxygenase inhibitors,
 5-lipoxygenase activating protein antagonists and/or leukotriene receptor
 antagonists. The composition may further comprise a decongestant.
 ACTIVITY - Antihistaminic; antiasthmatic; antiallergic;
 dermatological; antiinflammatory.
 USE - The compositions have potent anti-histaminic activity and are
 useful for treating, preventing or managing asthma, asthma symptoms,
 inflammation, allergic rhinitis and other allergic disorders, as well as
 dermatitis. The compositions are also useful in combination with
 non-steroidal anti-inflammatory agents or other non-narcotic analgesics
 for the treatment and prevention of cough, cold, cold-like and/or flu
 symptoms and the discomfort, headache, pain, fever and general malaise

associated with these. The compositions may also be useful for treating, preventing or managing motion sickness, vertigo, diabetic retinopathy, small vessel complications due to diabetes and similar conditions. The terfenadine metabolite and the leukotriene inhibitor have a synergistic effect.

ADVANTAGE - The composition may be used to treat, prevent or manage the disorders described while reducing or avoiding the adverse effects associated with the administration of other non-sedating antihistamines including terfenadine.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B06-A01; B06-B01; B06-D01; B06-D02; B06-F03; B07-D05; B10-A06; B10-B03B; B14-C01; B14-C03; B14-C04; B14-D05C; B14-K01A; B14-K01B; B14-L08; B14-L09; B14-N03; B14-N04; B14-N17C; **B14-S09**

ABEX

SPECIFIC COMPOUNDS - The terfenadine metabolite is racemic **fexofenadine** or (R) or (S) **fexofenadine** or 1-(p-(2-hydroxymethyl-2-propyl)phenyl)-4-(4-(alpha-hydroxy-alpha-phenylbenzyl)-1-piperidinyl)butanol. The 5-lipoxygenase inhibitor is zileuton, docebenone, piripost and/or ICI-D2318. The 5-lipoxygenase activating protein is MK-591 and/or MK-886. The leukotriene receptor antagonist is zafirlukast, **montelukast**, pranlukast, sodium 1-(((R)-(3-(2-(6,7-difluoro-2-quinolinyl)ethynyl)phenyl)-3-(2-(2-hydroxy-2-propyl)phenyl)thio)methyl)cyclopropaneacetate and/or 1-(((1(R)-(3-(2-(2,3-dichlorothieno(3,2-b)pyridin-5-yl)-(E)-ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid and their salts.

ADMINISTRATION - Administration may be concurrently or sequentially. Administration may be by any suitable route e.g. oral, intraoral, rectal, parenteral, epicutaneous, transdermal, subcutaneous, intramuscular, intranasal, sublingual, buccal, intradural, intraocular, intrarespiratory or by nasal inhalation. Oral administration is generally preferred, but in the treatment of dermatitis topical administration is preferred. Dosage of terfenadine metabolite is 0.01-500 (preferably 20-200) mg/day, in a single or divided doses. Decongestant, e.g. pseudoephedrine, is administered at 50-300 (preferably 150-250) mg/day. Dosage for leukotriene inhibitors depends on the compound employed e.g. for 5-lipoxygenase inhibitors the daily dosage is 20-2500 (preferably 20-800) mg; for leukotriene receptor antagonists, daily oral dosage is 2-100 (preferably 5-20) mg.

EXAMPLE - No examples given.

L119 ANSWER 8 OF 9 WPIX (C) 2003 THOMSON DERWENT

AN 1999-539829 [45] WPIX

DNC C1999-157680

TI Composition containing leukotriene antagonist and antihistamine, used for treating respiratory and skin diseases, effective against wide range of symptoms.

DC B02 B03 B05

IN DANZIG, M R; JENSEN, P K; LORBER, R R; MEDEIROS, P T

PA (SCHE) SCHERING CORP

CYC 84

PI WO 9932125 A1 19990701 (199945)* EN 22p A61K031-55

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
OA PT SD SE SZ UG ZW

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GD GE
HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MD MG MK MN MX NO
NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT UA US UZ VN YU

ZA 9811731 A 19990831 (199945) 17p A61K000-00

AU 9919071 A 19990712 (199950) A61K031-55

EP 1041990 A1 20001011 (200052) EN A61K031-55
 R: AT BE CH DE DK ES FI FR GB GR IE IT LI LT LU LV NL PT RO SE
 NO 2000003288 A 20000822 (200054) A61K031-55
 BR 9814417 A 20001010 (200055) A61K031-55
 CZ 2000002198 A3 20001115 (200064) A61K031-55
 SK 2000000897 A3 20010212 (200112) A61K031-55
 CN 1283115 A 20010207 (200129) A61K031-55
 KR 2001033485 A 20010425 (200164) A61K031-55
 MX 2000006254 A1 20010101 (200166) A61K031-445
 JP 2001526232 W 20011218 (200203) 26p A61K031-47
 HU 2001001369 A2 20020328 (200234) A61K031-55

ADT WO 9932125 A1 WO 1998-US26223 19981221; ZA 9811731 A ZA 1998-11731
 19981221; AU 9919071 A AU 1999-19071 19981221; EP 1041990 A1 EP
 1998-963828 19981221, WO 1998-US26223 19981221; NO 2000003288 A WO
 1998-US26223 19981221, NO 2000-3288 20000622; BR 9814417 A BR 1998-14417
 19981221, WO 1998-US26223 19981221; CZ 2000002198 A3 WO 1998-US26223
 19981221, CZ 2000-2198 19981221; SK 2000000897 A3 WO 1998-US26223
 19981221, SK 2000-897 19981221; CN 1283115 A CN 1998-812638 19981221; KR
 2001033485 A KR 2000-706986 20000622; MX 2000006254 A1 MX 2000-6254
 20000622; JP 2001526232 W WO 1998-US26223 19981221, JP 2000-525116
 19981221; HU 2001001369 A2 WO 1998-US26223 19981221, HU 2001-1369 19981221

FDT AU 9919071 A Based on WO 9932125; EP 1041990 A1 Based on WO 9932125; BR
 9814417 A Based on WO 9932125; CZ 2000002198 A3 Based on WO 9932125; JP
 2001526232 W Based on WO 9932125; HU 2001001369 A2 Based on WO 9932125

PRAI US 1998-78638P 19980319; US 1997-68638P 19971223

IC ICM A61K000-00; A61K031-445; A61K031-47; A61K031-55
 ICS A61K031-327; A61K031-352; A61K031-404; A61K031-4184; A61K031-4365;
 A61K031-4468; A61K031-454; A61K031-495; A61P011-00; A61P011-02;
 A61P011-06; A61P017-00; A61P017-04; A61P027-16; A61P037-08;
 A61P043-00

AB WO 9932125 A UPAB: 19991103
 NOVELTY - A pharmaceutical composition contains at least one leukotriene
 antagonist and at least one antihistamine.
 DETAILED DESCRIPTION - A pharmaceutical composition contains
 effective amounts of:
 (A) at least one leukotriene antagonist selected from the following
 compounds and their salts:
 (i) **montelukast**,
 (ii) 1-(((R)-(3-(2-(6,7-difluoro-2-quinolinyl)ethenyl)phenyl)-
 3-(2-(2-hydroxy-2-propyl)phenyl)thio) methylcyclopropane acetic acid;
 (iii) 1-(((1(R)-3(3-(2-(2,3-dichlorothieno (3,2-b)
 pyridin-5-yl)-(E)-ethenyl)phenyl)-3-(2-(1-hydroxy-1-
 methylethyl)phenyl)propyl)thio)methyl)cyclopropane acetic acid;
 (iv) **pranlukast**;
 (v) **zafirlukast**; or
 (vi) (2-((2-(4-tert. butyl-2-thiazolyl)-5-benzofuranyl)-
 oxymethyl)-phenyl) acetic acid; and
 (B) at least one antihistamine selected from
descarboethoxyloratidine, cetirizine,
fexofenadine, ebastine, astemizole,
norastemizole, epinastine, efletirizine and
 their salts.
 ACTIVITY - Dermatological; respiratory tract; antipruritic;
 antiinflammatory; antiallergic; antiasthma; analgesic; antitussive.
 MECHANISM OF ACTION - Leukotriene antagonist; antihistamine.
 USE - For treating diseases of the skin, the respiratory tract and/or
 associated symptoms (claimed). Typically the composition is effective
 against sneezing, itching runny nose, nasal congestion, redness of the
 eye, tears, itching of the ears or palate, shortness of breath,
 inflammation of the bronchial mucosa, reduced 'Force Expiratory Volume In
 One Second' (FEV1), coughs, rash, itchy skin, headaches, and aches and
 pains associated with seasonal or perennial allergic rhinitis, common
 colds, otitis, sinusitis, allergy, (allergic) asthma and/or inflammation.

ADVANTAGE - Inclusion of (B) improves the overall efficacy of (A) against the wide range of symptoms associated with respiratory disorders such as allergic rhinitis, colds and sinusitis.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B06-H; B07-H; B14-K01; B14-K01E; B14-L09; B14-N17

TECH UPTX: 19991103

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Components: (A) is **montelukast** or **pranlukast**; and (B) is **cetirizine**, **fexofenadine**, **ebastine**, **norastemizole**, **efletirizine** or especially **descarboethoxyloratidine**. The composition optionally contains a third active ingredient (C), selected from decongestants (specifically pseudoephedrine), cough suppressants (specifically dextromethorphan), expectorant/mucolytic agents (specifically guaifenesin) and analgesics.

ABEX

ADMINISTRATION - Administration is generally oral. Unit dose is 5-500 mg for (A). An especially preferred composition comprises 10 mg **montelukast** and 5 mg or 7.5 mg **descarboethoxyloratidine**.

EXAMPLE - None given.

L119 ANSWER 9 OF 9 WPIX (C) 2003 THOMSON DERWENT

AN 1997-415060 [38] WPIX

DNC C1997-132840

TI Composition comprising **loratadine** and leukotriene antagonist - used for treatment of asthma, allergy and inflammation.

DC B02

IN DAHLEN, S; SCOLNICK, E M

PA (MERI) MERCK & CO INC

CYC 75

PI WO 9728797 A1 19970814 (199738)* EN 11p A61K031-41

RW: AT BE CH DE DK EA ES FI FR GB GR IE IT KE LS LU MC MW NL OA PT SD
SE SZ UG

W: AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HU IL IS JP KG KR KZ
LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT
UA US UZ VN YU

AU 9722579	A	19970828 (199750)	A61K031-41
NO 9803641	A	19980807 (199846)	A61K031-47
CZ 9802487	A3	19990113 (199908)	A61K031-41
JP 11504044	W	19990406 (199924)	A61K031-445
SK 9801056	A3	19990507 (199926)	A61K031-41
CN 1210465	A	19990310 (199929)	A61K031-41
BR 9707369	A	19990720 (199940)	A61K031-41
HU 9901860	A2	19991228 (200010)	A61K031-41
EP 1014972	A1	20000705 (200035) EN	A61K031-41

R: AT BE CH DE DK ES FI FR GB GR IE IT LI LT LU LV NL PT RO SE SI			
NZ 331160	A	20000728 (200043)	A61K031-41
KR 99082367	A	19991125 (200055)	A61K031-41
MX 9806421	A1	19990201 (200055)	A61K031-41
AU 732671	B	20010426 (200128)	A61K031-41

ADT WO 9728797 A1 WO 1997-US1799 19970204; AU 9722579 A AU 1997-22579 19970204; NO 9803641 A WO 1997-US1799 19970204, NO 1998-3641 19980807; CZ 9802487 A3 WO 1997-US1799 19970204, CZ 1998-2487 19970204; JP 11504044 W JP 1997-528627 19970204, WO 1997-US1799 19970204; SK 9801056 A3 WO 1997-US1799 19970204, SK 1998-1056 19970204; CN 1210465 A CN 1997-192149 19970204; BR 9707369 A BR 1997-7369 19970204, WO 1997-US1799 19970204; HU 9901860 A2 WO 1997-US1799 19970204, HU 1999-1860 19970204; EP 1014972 A1 EP 1997-905757 19970204, WO 1997-US1799 19970204; NZ 331160 A NZ 1997-331160 19970204, WO 1997-US1799 19970204; KR 99082367 A WO 1997-US1799 19970204, KR 1998-706097 19980807; MX 9806421 A1 MX 1998-6421 19980807; AU 732671 B AU 1997-22579 19970204

FDT AU 9722579 A Based on WO 9728797; CZ 9802487 A3 Based on WO 9728797; JP 11504044 W Based on WO 9728797; BR 9707369 A Based on WO 9728797; HU 9901860 A2 Based on WO 9728797; EP 1014972 A1 Based on WO 9728797; NZ 331160 A Based on WO 9728797; KR 99082367 A Based on WO 9728797; AU 732671 B Previous Publ. AU 9722579, Based on WO 9728797

PRAI GB 1996-8927 19960429; US 1996-11328P 19960208

REP US 4282233; US 4847275; US 5030643; US 5270324; US 5472964; US 5565473

IC ICM A61K031-41; A61K031-445; A61K031-47

ICS A61K031-40; A61K031-405; A61K031-44

AB WO 9728797 A UPAB: 19970922

Novel composition comprises as active ingredients **loratadine** and a leukotriene antagonist, selected from: (a) **montelukast** sodium; (b) sodium-1-((R)-(3-(2-(6,7-difluoro-2-quinolinyl)ethenyl)phenyl)-3-(2-(2-hydroxy-2-propyl)phenyl)thio)methylcyclopropaneacetate; (c) 1-(((1(R)-(3-(2-(2,3-dichlorothieno[3,2-b]pyridin-5-yl)-(E)-ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid or a sodium salt; (d) pranlukast; and (e) zafirlukast.

USE - The formulation can be used for the treatment of asthma, allergy and inflammation (claimed).

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B06-D02; B06-D13; B06-F03; B14-C03; B14-G02A; B14-K01A

=> d his

(FILE 'HOME' ENTERED AT 13:30:15 ON 09 MAR 2003)
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 13:30:28 ON 09 MAR 2003

E HARRIS A/AU

L1 122 S E3,E14

L2 55 S E56,E57,E60,E61

L3 2 S E106,E107

E MEDEIROS P/AU

L4 7 S E4-E6,E9

L5 13116 S (SCHERING? OR PLOUGH?)/PA,CS

L6 6 S L1-L4 AND L5

L7 1 S DESCARBOETHOXYLORATIDIN?

L8 1402 S DESLORATADIN? OR CETIRIZIN? OR FEXOFENADIN? OR EBASTIN? OR AS

FILE 'REGISTRY' ENTERED AT 13:36:29 ON 09 MAR 2003

L9 8 S (DESLORATADINE OR CETIRIZINE OR FEXOFENADINE OR EBASTINE OR A
E DESCARBOETHOXYLORATIDINE/CN

L10 1 S E2

L11 8 S L9,L10

SEL RN

L12 64 S E1-E8/CRN

E MONTELUKAST/CN

L13 1 S E3

E C35H36CLNO3S/MF

L14 6 S E3 AND C6/ES AND C3/ES AND NC5-C6/ES AND 5/NR

L15 1 S L14 AND MONTELUKAST

L16 5 S L14 NOT L15

L17 3 S L16 NOT (142264-89-9 OR 142522-33-6)

L18 4 S L13,L15,L17

SEL RN

L19 6 S E1-E4/CRN

L20 1 S L12 AND L19

L21 5 S L19 NOT L20

L22 63 S L12 NOT L20

L23 31 S L22 NOT (MXS/CI OR COMPD OR WITH)

FILE 'HCAPLUS' ENTERED AT 13:43:53 ON 09 MAR 2003

L24 1334 S L11 OR L23

L25 1583 S L7,L8,L24

L26 208 S L18 OR L21

L27 254 S MONTELUKAST OR L26

L28 39 S L25 AND L27

L29 1 S L20

L30 2 S L1-L4 AND L28

L31 1 S L1-L4 AND L29

L32 2 S L5 AND L28,L29

L33 2 S L30-L32

E ANTIHISTAMINE/CT

L34 6849 S E4-E7,E10-E13

E E10+ALL

L35 4406 S E1

E E2+ALL

L36 3750 S E4+NT

L37 6849 S L34-L36

L38 7027 S L26,L37

E LEUKOTRIENE ANTAGONIST/CT

L39 373 S E4

E E4+ALL

L40 401 S E4

L41 928 S L39,L40,L27

L42 282 S L38 AND L41

E CARDIOVASCULAR/CT

L43 60712 S E5+NT

E E5+ALL

E E20+ALL

L44 313709 S E3+NT

E CARDIOVASCULAR/CT

L45 16442 S E12-E13

E E12+ALL

E CARDIOVASCULAR/CT

E E6+ALL

L46 6760 S E2

E HEART/CT

L47 183960 S E3+NT

E E113+ALL

E E2+ALL

L48 62164 S E3+NT

E BLOOD VESSEL/CT

L49 130122 S E3+NT

L50 83264 S E61+NT

L51 1359 S E94

E E3+ALL

L52 3173 S E5

E E25+ALL

E ARTERY/CT

L53 61697 S E3+NT

L54 42148 S E110+NT

E E110+ALL

L55 646 S E40+NT

E VEIN/CT

L56 11677 S E3+NT

L57 282 S E59

E E10+ALL

L58 811 S E6

E CAPILLAR/CT

E E11+ALL

E E3+ALL

L59 7069 S E6,E5+NT
 L60 54 S L42 AND L43-L59
 E RESPIRATORY TRACT/CT
 L61 129842 S E3+NT
 E E3+ALL
 L62 21091 S E33+NT OR E34+NT
 L63 613 S E4(L)UPPER
 L64 87 S L42 AND L61-L63
 E SKIN/CT
 L65 79719 S E3+NT
 E E3+ALL
 E E33+ALL
 L66 50649 S E3+NT
 L67 34 S L42 AND L65,L66
 L68 21 S L60 AND L64,L67
 L69 53 S L28,L68
 L70 38 S L28 AND L42,L65,L66,L60,L64,L67,L68
 L71 283 S L28,L42,L64,L67,L69,L70
 L72 174 S L71 AND (PD<=20001030 OR PRD<=20001030 OR AD<=20001030)
 L73 93 S L72 AND (COMBIN? OR COMPOSITION OR SYNERG? OR MIX? OR ADMIX?)
 L74 81 S L72 NOT L73
 L75 2 S L74 AND L25
 L76 30 S L73 AND L25
 L77 49 S L28,L76
 L78 31 S L77 AND (PD<=20001030 OR PRD<=20001030 OR AD<=20001030)
 L79 30 S L78 AND (COMBIN? OR COMPOSITION OR SYNERG? OR MIX? OR ADMIX?)
 L80 1 S L78 NOT L79
 L81 28 S L79 AND L24
 L82 19 S L81 AND L26
 SEL DN AN 3 7 8 17 18 19
 L83 6 S E1-E18
 L84 9 S L81 NOT L82
 SEL DN AN 5 7
 L85 2 S L84 AND E19-E24
 L86 8 S L29,L33,L83,L85 AND L1-L8,L24-L85
 L87 8 S L86 AND (LEUKOTRIEN? OR ?HISTAMIN? OR ?LORATADIN? OR CETIRIZI
 L88 6 S L87 AND MONTELUKAST
 L89 8 S L87,L88

FILE 'REGISTRY' ENTERED AT 14:14:58 ON 09 MAR 2003

FILE 'HCAPLUS' ENTERED AT 14:16:14 ON 09 MAR 2003

L90 9 S (WO9303723 OR DE4203201 OR WO9728797 OR EP0565185 OR EP078012
 L91 8 S L90 NOT L89
 L92 8 S L91 AND L1-L8,L24-L91
 L93 3 S L92 AND L11,L12,L18,L20,L23
 L94 8 S L92,L93

FILE 'EMBASE' ENTERED AT 14:20:40 ON 09 MAR 2003

L95 4070 S L11
 L96 5076 S ?LORATADIN? OR ?LORATIDIN? OR CETIRIZIN? OR FEXOFENADIN? OR E
 L97 5076 S L95,L96
 L98 1026 S L18
 L99 1039 S MONTELUKAST
 L100 1039 S L98,L99
 L101 137 S L97 AND L100
 L102 57 S L101 AND PY<=2000
 L103 25 S L102 AND CB/CT
 L104 10 S L100 (L) CB/CT AND L102
 L105 17 S L97 (L) CB/CT AND L102
 L106 18 S L104,L105
 L107 9 S L106 AND L104 AND L105
 L108 4 S L107 NOT AB/FA

L109 5 S L107 NOT L108
L110 9 S L106 NOT L107

FILE 'EMBASE' ENTERED AT 14:26:10 ON 09 MAR 2003

FILE 'WPIX' ENTERED AT 14:26:29 ON 09 MAR 2003

L111 268 S L96/BIX
L112 43 S L99/BIX
L113 20 S L111 AND L112
L114 3 S L113 AND (B14-S09 OR C14-S09 OR B12-C09 OR C12-C09)/MC
L115 3 S L113 AND P861/M0,M1,M2,M3,M4,M5,M6
L116 3 S L114,L115
L117 17 S L113 NOT L116
SEL DN AN 2 5 6 15 16 17
L118 6 S L117 AND E25-E36
L119 9 S L116,L118

FILE 'WPIX' ENTERED AT 14:33:28 ON 09 MAR 2003